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ABSTRACT 
Two studies were designed to characterize the effects of a non-steroidal aromatase inhibitor, 
letrozole, on ovarian function in cattle. The specific objective was to test the hypothesis that 
letrozole will arrest dominant follicle growth resulting in emergence of a new follicular wave at a 
predictable interval post-treatment. In a first experiment, postpubertal beef heifers were assigned 
randomly to four treatment groups and given phosphate-buffered saline (controls; n=10), or 
letrozole at a dose of 500 (n=9), 250 (n=10), or 125 (n=10) µg/kg intravenously 4 days after 
follicular ablation (~2.5 days after wave emergence). In a second study, postpubertal beef heifers 
were assigned randomly to four treatment groups. One group received no treatment (control; 
n=17) and the other groups (n=9-10) were given 85 µg/kg of letrozole per day (250 µg/kg total 
dose), from Days 1 to 3, Days 3 to 5, or Days 5 to 7 (Day 0 = pre-treatment ovulation,) 
corresponding to the periods before, during and after selection of the dominant follicle, 
respectively. Follicular dynamics were monitored ultrasonically and blood samples were 
collected for endocrine assays. Follicle diameter profiles and plasma LH, FSH, and estradiol 
concentrations were analyzed. Additionally, during the second trial, CL diameter profiles and 
plasma progesterone concentrations were measured.  In both studies, the diameter profile of the 
dominant follicle was larger in heifers treated with letrozole than in control heifers (P<0.05) and 
the intervals to new wave emergence and onset of regression of the extant dominant follicle were 
longer (P<0.05) in heifers treated with letrozole than in controls, regardless of the dose (high, 
medium, or low; single vs multiple) and the stage of the follicle wave in which treatments were 
initiated. Furthermore, during the second experiment, the mean CL diameter was larger in 
letrozole-treated heifers, although there were no differences in plasma progesterone 
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concentrations between treated and control animals. The effects on dominant follicle and CL 
diameter profiles appeared to be the result of the significantly increased plasma LH 
concentrations observed in letrozole-treated animals during both treatment approaches (single vs 
multiple dose). Incomplete and inconsistent inhibition of estradiol production and the lack of a 
surge on FSH observed in both experiments may be a result of insufficient circulating levels of 
letrozole during the treatment period. In summary, a single or multiple dose of letrozole did not 
induce regression of the extant dominant follicle, nor did it directly affect FSH release. 
Conversely, letrozole extended the lifespan of the dominant follicle, in association with increased 
endogenous levels of LH, thereby delaying the next FSH surge and subsequent follicular wave 
emergence. Results suggest that letrozole has potential as a non-steroidal method for controlling 
ovarian function in cattle, but further studies are warranted to clarify dosage and timing of 
treatment to predictably affect follicular wave dynamics in cattle.  
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1.1. GENERAL INTRODUCTION 
Reproductive efficiency is the single most important factor affecting profitability in the 
cattle industry. Improvements in reproductive efficiency have required years of research aimed at 
clarifying and describing the patterns and mechanisms governing physiological functions related 
to reproduction. Key findings such as the occurrence of waves of follicular growth [1, 2] and the 
involvement of gonadotrophins [3-5] and steroid hormones [6, 7] in the control of follicular 
wave patterns have allowed the development and application of several strategies meant to 
manipulate the many different events related to ovarian function in cattle. Among those 
strategies, estrogens in combination with a source of progesterone has been very efficient in 
synchronizing follicle wave emergence and ovulation [8, 9]. Steroid-induced wave 
synchronization is associated with regression of the dominant follicle followed by a surge in 
circulating FSH and subsequent emergence of a new follicular wave at a consistent interval post-
treatment. Steroid-induced regression of the dominant follicle is a result of a systemic alteration 
in feedback of estradiol and progesterone on pituitary release of LH and FSH [10]. Estradiol 
suppresses FSH release [11] and has been reported to decrease LH pulse amplitude in sheep [12] 
and cattle [13]. Progesterone has been reported to decrease LH pulse frequency and suppress 
maximal diameter of the dominant follicle in a dose-dependent manner in cattle [14-19]. Once 
the suppressive effects of estradiol are removed, FSH surges resulting in the emergence of a new 
wave of follicular development approximately 4 days after estradiol/progesterone treatment, 
regardless of the stage of development of the dominant follicle at the time of treatment [9, 20, 
21]. The degree of synchrony achieved with a combination of estradiol and progesterone has 
reduced or eliminated the need for estrus detection, allowing more efficient use of time and 
labour, and thereby shortening breeding and calving seasons. Furthermore, the elective control of 
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follicle development in cattle has opened the possibility of introducing new technologies that 
require precise control of luteal function, follicle wave emergence and ovulation such as fixed-
time artificial insemination (FTAI) [22, 23] and multiple ovulation and embryo transfer (MOET) 
[9, 24].  
Estrogens regulate reproductive phenomena and play a key role in many other important 
physiological functions in vertebrates. Because of their involvement in the determination of 
secondary sexual characteristics,  acceleration of linear growth and closure of epiphyseal plates,  
and facilitation of fat deposition and vasodilatation [25], estrogen and its synthetic analogs have 
been used by the beef industry as growth promoting factors for several decades [26]. It has been 
reported that the anabolic effects of implants containing estrogens can improve growth rate by 10 
to 30% and feed efficiency by 5 to 15% [27, 28]. 
The concern regarding the toxicity of hormonal preparations used as growth promoters in 
cattle, and the potential carcinogenic effects of hormonal residues present in meat or milk of 
treated animals [29-31] was raised in Europe more than 20 years ago. The use of naturally 
occurring estrogens and synthetic compounds with estrogenic activity in food producing animals 
has been a subject of considerable controversy (reviewed in [32]). After years of deliberation, 
and regardless of the lack of convincing scientific support, the European Union (EU) decided to 
ban the use of estradiol and other steroid hormones as growth promoting agents in animals 
designated for human consumption in all the member states as of January 1, 1989 [33]. This 
prohibition also banned the entry into the EU of meat or food products originated from animals 
in which hormonal growth promoting treatments were applied. As there was some uncertainty 
among veterinarians regarding the legality of using hormonal treatments for reproductive 
management in animals designated to human consumption, the EU issued another report, 
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officialised on October 14, 2006, in which it was stated that the use of estradiol-17β and its ester 
derivatives for reproductive management was also prohibited [34]. These legislations led to the 
ban of the use of estradiol esters in lactating dairy animals in New Zealand and Australia in 2007 
[35]. the use of estradiol and estrogen-like compounds as growth promoters is still permitted in 
the United States [36] and Canada [37]. However, they can only be applied for the purpose of 
estrus synchronization following prescription and compounding, and compounding of drugs for 
use in food-producing animals raises additional problems in the USA [38, 39]. The ban of the use 
of estrogens in livestock and lack of commercially available of estrogenic preparations 
negatively impacts the implementation of reproductive biotechnologies in cattle production 
systems, limiting potential reproductive efficiency and genetic improvement provided by the use 
of AI or MOET [35]. In this context, the development of alternative methods for controlling 
ovarian function in cattle, with efficacy and predictability comparable with that of estrogen plus 
progesterone treatments [21], and with no toxic or harmful effects on human and animal health is 
needed. 
Aromatase inhibitors prevent the body from producing its own estrogens. Thus, they could 
potentially be applied to the management of estrogen-dependent physiologic functions such as 
reproduction. Letrozole is a non-steroidal aromatase inhibitor that inactivates the aromatase 
enzyme by reversibly binding to the heme group of the P450 subunit of the enzyme. It was 
developed and is prescribed as an adjuvant treatment as well as a first line treatment of 
hormonal-responsive breast cancer in post-menopausal women [40].  
Letrozole has been used in human assisted reproduction to treat sub-fertile and infertile 
women because of its effectiveness in removing the negative feedback effect of estradiol on 
gonadotrophin  secretion [41]. There is no commercially available formulation of letrozole 
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labelled for such purposes; however the protocols have been developed as an off-label 
instruction. Several authors have reported using of letrozole in a 5-day regimen starting 3 days 
after the beginning of menses for ovarian stimulation [42-45] and it has also been used in higher 
or increasing doses to induce  ovarian superstimulation in women [46, 47]. It can be 
hypothesized that letrozole could be applied to the management of ovarian function in cattle, 
even though the exact mechanism of stimulation of ovarian function by letrozole is not clearly 
understood. 
1.1. Reproductive Physiology in Cattle 
1.1.1. Follicular wave development in cattle 
In cattle, ovarian follicles develop in waves [1, 2]. An ovarian follicular wave begins with 
the synchronous development of a group of follicles (7 to 11) ≥4 mm in diameter. This period is 
refered to as wave emergence [48]. In monovular species such as cattle, a single follicle is 
selected from this cohort of follicles to continue growth (dominant follicle) while the other 
follicles undergo atresia (subordinate follicles) [1, 49-51]. The occurrence of selection is 
confirmed by the deviation in diameter between the dominant follicle and the largest subordinate 
follicle which occurs when the dominant follicle is on average 8.5 mm in diameter. That is, about 
3 days after wave emergence [48]. If the dominant follicle grows during the early luteal phase, 
the follicle becomes an anovulatory follicle and regresses. During anovulatory waves, three 
different phases of follicular growth have been described: 1) a growing phase during which the 
dominant follicle grows actively; 2) a static phase during which follicular diameter does not 
change; and, 3) a regressing phase during which follicular diameter starts to decrease [52]. 
However, if the dominant follicle is in its growing or early static phase when the regression of 
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the corpus luteum begins it will become the ovulatory follicle and it has the potential to trigger 
the gonadotrophin surge that will lead to ovulation (reviewed in [53]).   
Two and three of these waves of follicular development have been commonly reported 
during an estrous cycle in cattle. There has been some controversy about the frequency of these 
patterns; some authors reported a higher incidence of animals with two waves of follicular 
development while other research groups reported that cycles with three waves were more 
frequently found than those with two waves [51, 52, 54, 55]. In animals with two or three waves 
of follicular development, the first wave can be identified, on average, the day of ovulation. The 
second wave appears by day 10 after ovulation in two-wave cycles [52] and by day 9 in three-
wave cycles, and in this last group the third wave is detected by day 16 [56]. Furthermore, it has 
been shown that estrous cycles composed of two waves are consistently shorter than cycles with 
three waves of follicular development (19 to 20 days and 22 to 23 days, respectively) [56]. 
1.1.2. Role of gonadotrophins in ovarian functions 
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) play crucial roles in the 
regulation of the ovarian follicular dynamics. Emergence of a follicular wave and the selection of 
the dominant follicle have been temporally associated with an increase and decrease, 
respectively, in FSH levels. A transient increase in plasma LH concentration has also been 
reported in relation to the time of follicular deviation (defined as the measure point when a 
significant difference in diameter between the dominant follicle and the largest subordinate 
follicle is first identified), besides the well documented peak in LH concentrations that 
encompasses ovulation [4, 5]. It has been demonstrated that each wave of follicular development 
is preceded by a surge in FSH concentration [3]. In this regard, the suppression of the increase in 
FSH concentration by administration of a proteinaceous fraction of follicular fluid was followed 
6 
 
by a delay on follicular wave emergence. Moreover, promotion of a surge of FSH by ablation of 
the extant DF resulted in the emergence of a new wave of follicular development within 2 days. 
These results also provided evidence that intrafollicular factors were, at least in part, responsible 
for the changes in plasma FSH concentrations related to follicular dynamics. Further clarification 
of this concept revealed that increasing plasma concentrations of intrafollicular components (e.g., 
estradiol, inhibins, insulin-like growth factors, etc), mainly synthesised by the dominant follicle, 
had a suppressing effect of circulating FSH concentrations and that the decrease in FSH levels 
was crucial for the selection process and to ensure monovulation by regression of the subordinate 
follicles [57] (reviewed in [49, 58]). A FSH-follicle coupling system involving all the follicles in 
a wave is responsible for the initial drop in FSH concentrations observed after wave emergence. 
When the dominant follicle reaches a critical stage of development (which has been identified as 
8.5 mm [59]) it has the capability to further suppress FSH concentrations to levels that are not 
compatible with continuous development of the subordinate follicles which then undergo atresia. 
However, the dominant follicle can continue growing for a longer period of time, even under 
very low levels of plasma FSH [60]. The acquisition of LH receptors by the thecal and granulosa 
cells of the dominant follicle contribute in part to the ability of the dominant follicle to remain 
viable in a low FSH environment [61]. Results of a study involving the suppression of the 
transient LH rise before, during and after follicular deviation by administration of exogenous 
progesterone demonstrated that LH was not indispensable for the initiation of deviation; there 
was no difference in follicle diameters between progesterone-treated and control animals before 
and during deviation. However, it was observed that the dominant follicle was smaller and grew 
at a slower rate than dominant follicle of control animals when LH secretion was suppressed 
after deviation was initiated. [61]. Meanwhile, the active dominant follicle continues to produce 
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factors that inhibit plasma FSH secretion ensuring that the emergence of a new wave of follicular 
development will not occur throughout the dominance period [62]. Once the dominant follicle is 
at the end of the static phase and starts to regress, plasma concentration of follicular components 
start to decline removing the FSH-suppressing effects of estradiol. A surge of FSH is observed 
followed by the development of a new follicular wave.  
In summary, follicle wave emergence is preceded by an increase in plasma FSH 
concentrations. Follicular selection is related to a decline in FSH concentrations caused mainly 
by the production of estradiol by the dominant follicle under the influence of LH. Low FSH 
concentrations maintained by the dominant follicle ensure that no further waves of follicular 
development occur during the period of dominance. When LH pulse frequency is low the 
dominant follicle losses dominance and regresses, estradiol production declines and FSH 
increases and a new wave of follicular development is stimulated. However, if the dominant 
follicle is still viable at the end of the luteal phase, LH pulse frequency increases and stimulates a 
greater production of estradiol by the dominant follicle that will, in turn, elicit a preovulatory 
peak of LH and FSH secretion, and ovulation. The disappearance of the dominant follicle after 
ovulation removes the negative feedback effect of estradiol on FSH secretion and a post-
ovulatory surge of FSH followed by the emergence of a wave of follicular development is 
observed [63]. 
1.2. Control of the estrous cycle 
The advancement in our understanding of reproductive biology in cattle has made it possible 
to develop several strategies and protocols to manipulate phenomena related to the estrous cycle 
i.e., wave emergence, selection, luteolysis and ovulation. The ideal method of control of the 
estrous cycle is the one that is simple, effective and safe. For the purpose of this introduction, 
8 
 
some aspects of those strategies using prostaglandin F2α (PGF) and gonadotrophin releasing 
hormone (GnRH), and the rationale and implementation of protocols based on the use of 
estrogens alone or in combination with progesterone releasing devices will be briefly reviewed.  
1.2.1. Prostaglandin and GnRH-based protocols for estrus synchronization  
The identification of PGF as the luteolysin responsible for the regression of the CL in cattle 
provided a new means for controlling of the length of the luteal phase and ovulation (reviewed in 
[64]). Several protocols using different doses and intervals between doses of prostaglandins have 
since been designed [65, 66]. The state of maturity of the dominant follicle at the time of PGF 
treatment determines the interval to estrus and ovulation (on average, 3 to 3.4 days). However, if 
the extant dominant follicle is in the late static or regressing phase at the time of PGF treatment, 
the dominant follicle of the subsequent follicular wave will grow and reach preovulatory size; the 
process that may take as much as 4.5 days [65, 66]. Further, newly formed CL during the first 3 
to 4 days after ovulation are refractory to the luteolytic effect of PGF and responsiveness 
increases as the CL develops [65]. These important sources of variability in interval from 
treatment to ovulation limit the use of prostaglandin-based protocols for fixed-time artificial 
insemination (FTAI). A treatment approach using two injections of PGF 11 to 14 days apart is 
widely accepted and used mainly on dairy farms. The rationale for this approach is that 
approximately 67% of the animals (those with a CL 5 days old or older and experiencing natural 
luteal regression) would respond to the first injection by undergoing luteolysis and ovulating. 
Therefore, 100% of the animals would have a functional and responsive CL when the second 
injection of PGF is administered 11 to 14 days later [50]. However, the use of luteolytic doses of 
prostaglandin still relies on estrus detection efficiency to provide acceptable outcomes. 
Consequently, the low rate of submission of animals for artificial insemination (AI) after 
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detected estrus, reported to be about 50% in North America [67], limits the effectiveness of this 
protocol.  
Fixed-time AI eliminates the need for estrus detection but requires synchronous ovulation. 
The use of FTAI can overcome the negative impact of poor estrus detection efficiency. 
Pregnancy rates obtained with FTAI are usually comparable to those obtained after AI with high 
estrus detection rates, because all animals are inseminated regardless of whether or not they 
showed estrus [68]. Gonadotrophin releasing hormone (GnRH) is commonly used to induce the 
pituitary release of gonadotrophins (LH and FSH) which will induce ovulation and/or 
luteinisation of the dominant follicle [6, 69]; this is followed by the emergence a new wave of 
follicular development approximately 2 days after GnRH treatment [69]. The use of GnRH is 
usually combined with a luteolytic dose of PGF 7 days later. The GnRH is intended to 
synchronize wave emergence and the PGF synchronizes luteolysis. An additional dose of GnRH 
is used about 48 hours after PGF to induce an LH surge and synchronize ovulation [68, 70]. 
Finally, animals are inseminated 16 to 20 hours after the second GnRH dose. This protocol is 
known as the Ovsynch. Several studies in which Ovsynch protocols were used had pregnancy 
rates similar to those obtained using the two doses of PGF 14 days apart with high estrous 
detection management in lactating dairy cows (38.9% versus 37.8%) [68, 69]. However, when 
the same protocols were applied to heifers, pregnancy rates following Ovsynch were lower than 
in controls treated with PGF and inseminated after estrus detection (35.1% versus 74.4%). Poor 
ovulatory response to the first injection of GnRH and consequently poor synchronization of 
wave emergence were identified as the causes of the lack of success of the Ovsynch protocols in 
heifers [71]. 
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1.2.2. Estradiol and progesterone-based protocols 
The interval from PGF-induced luteolysis to ovulation and the variability in the ovulatory 
response among animals to GnRH treatment depends on the status of the ovarian follicle at the 
time of treatment. Thus, a method that controls ovarian follicle recruitment would provide the 
advantage of knowing the stage of follicular development when the ovulatory or luteolytic 
treatment is given and improve the degree and synchrony of the ovulatory response. A 
synchronized ovulatory response is essential for the efficient use of time, resources, labour and 
the application of reproductive management techniques such as FTAI [21, 24] and MOET [72, 
73].  
A combination of progesterone and estradiol have been used to hormonally ablate the effects 
of the dominant follicle and to induce a new wave of follicular development in a predictable 
interval of time [13, 21]. This method of synchronizing wave emergence is based on the negative 
feedback effects that estradiol has on FSH secretion during the luteal phase [74] or under the 
influence of an exogenous source of progesterone [9, 20, 21, 73]. Furthermore, exogenous 
progesterone suppresses LH secretion leading to the regression of the extant dominant follicle. 
Reducing circulating levels of FSH and LH terminates the growth of both FSH- and LH-
dependent follicles, and the subsequent increase in FSH results in the emergence of a new wave 
of follicular development about 4 days after estradiol and progesterone treatment [9, 72]. The 
complete protocol includes the insertion of a progesterone releasing device for 7 to 9 days plus a 
dose of estradiol at the time of device insertion and a dose of PGF at the time of progesterone 
device removal to ensure luteal regression. Animals are inseminated 55 to 60 hours after 
progesterone withdrawal [75]. Different forms of estradiol have been applied in these progestin-
based protocols. It has been reported that the use of short-acting preparations such as estradiol-
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17β  (E-17β) or estradiol benzoate (EB) results in more synchrony of wave emergence and 
ovulation than long-acting esters [76]. In a trial in which estradiol cypionate (ECP) was given  in 
combination with a controlled internal drug release device (CIDR) of progesterone to 
synchronize wave emergence and ovulation [77], synchrony of wave emergence were less 
precise and the interval to ovulation was more variable than in animals treated with EB or E-17β. 
The synchrony associated with ECP was attributed to the longer absorption period from the site 
of injection and the length of action in the circulation. However, in a later study, the same group 
reported pregnancy rates after FTAI with ECP that were comparable with those obtained using 
EB or E-17β (approximately 56.4%) [24]. It is important to point out that, in this last experiment, 
an additional dose of ECP or EB used 0 to 24 hours after CIDR removal was used to synchronize 
ovulation.  
The effects of short-acting estradiol preparations in progesterone-treated cows on synchrony 
of wave emergence and ovulation have been of critical importance for the application of 
superstimulation protocols for MOET programs [78]. The outcome of a superstimulation 
treatment is strongly influenced by the stage of follicular development at initiation of treatment. 
Optimal ovarian responses were obtained when superstimulatory treatments were initiated about 
the time of follicular wave emergence (day – 1 or 0 of the follicular wave) [21], as observed 
when treating between days 8 and 12 after estrus detection (around the time of emergence of the 
second follicular wave) [24]. Since progesterone plus estradiol treatments result in precise 
synchronization of wave emergence (on average 4.3 days after treatment), superstimulatory 
treatments are initiated on the day of wave emergence (day 4), without the need for estrus 
detection and the 8- to 12-day waiting period [9, 79].  
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1.3.  Estrogens and other sex steroid hormones 
1.3.1. Steroidogenic pathway 
Steroid hormones are cholesterol-derivatives commonly classified in five groups: 
glucocorticoids, mineralocorticoids, androgens, progestins and estrogens. The last three groups 
are also referred to as sex steroid hormones, since they are involved in mechanisms that control 
reproductive physiology in mammals. Estrogens are composed of 18 carbon molecules and are 
the final product of a complex biosynthetic pathway that, in ruminants, involves five main 
enzymes. The rate limiting step in the biosynthesis of sex steroids is the incorporation of 
cholesterol into the mitochondria. Free cholesterol is highly hydrophobic, and although it can 
cross the cellular membrane by diffusion, this process is extremely slow. Therefore, this step 
depends on an active mechanism to transverse the hydrophobic mitochondrial wall. This process 
is mediated by the “steroidogenic acute regulatory protein” (StAR). Once inside the 
mitochondria, cholesterol is metabolized to pregnenolone by the P450 cholesterol side-chain 
cleavage enzyme (P450scc). Pregnenolone is the substrate for two different enzymes: 3β-
hydroxysteroid dehydrogenase (3β-HSD) and cytochrome P450 17α-hydroxylase (P45017-OH), 
giving rise to progesterone and 17α-hydroxypregnenolone, respectively. In ruminants, granulosa 
cells only express 3β-HSD. Consequently, progesterone is the main product and these cell types 
cannot metabolize it further. In thecal cells, however, P45017-OH is highly expressed and 
pregnenolone is mainly converted into 17α-hydroxypregnenolone. The 17α-
hydroxypregnenolone is then converted into androstenedione by the sequential activities of 
P45017-OH and 3β-HSD and a small amount of androstenedione is transformed into testosterone 
by the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD). Both androgens, androstenedione 
and testosterone, are then available to be either secreted or further converted into estrone and 
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estradiol, respectively, by the action of the cytochrome P450 aromatase (P450arom) within the 
granulosa cells [80, 81]. The major enzymatic pathway leading to the synthesis of estrogens, 
irrespective of species or tissue, is summarized in the Figure 1.1. 
 
 
Fig. 1.1. Synthesis of estrogens in ruminants. Five main hormones are involved in the enzymatic 
pathway leading to the synthesis of estrogens from cholesterol. 
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1.3.2. Regulation of steroidogenesis in bovine ovary 
Timely variations in the expression and number of gonadotrophin receptors (LH receptor 
LHr, and FSH receptor FSHr) as well as differences in cell responsiveness to the activation of 
such receptors have been described during folliculogenesis and maturation of ovarian follicles in 
cattle [82]. Researchers have been able to relate the changes in expression and activity of the 
gonadotrophin receptors with the control of steroidogenesis in the bovine ovary, and ultimately, 
with the ovarian follicular dynamics [80, 81]. It was shown that FSHr mRNA was expressed in 
granulosa and cumulus cells of pre-recruitment ovarian follicles, although this stage of follicular 
development has been classified as gonadotrophin-independent. The beginning of recruitment of 
such follicles into a wave has been associated with the expression of P450arom and P450scc 
mRNA in their granullosa cells. It is believed that the surge in FSH related to wave emergence 
[3] could be responsible for the induction of such enzymes in the granulosa cells. As the thecal 
cells of pre-antral and small antral follicles are already expressing LHr mRNA, P450scc mRNA, 
3β-HSD mRNA, StAR mRNA and P45017-OH mRNA, and are therefore producing androgens, 
recruited follicles begin to synthesize and secrete estradiol.  
By the time of dominant follicle selection, several follicles in the cohort begin to express 
LHr mRNA and 3β-HSD mRNA on their granulosa cells. It has been hypothesized that estradiol 
and FSH induce these changes, since LHr mRNA and 3β-HSD mRNA are expressed in the 
follicles with higher levels of P450arom and P450scc mRNA in granulosa cells (both enzymes 
induced by FSH for the synthesis of estrogens). Forty eight hours after wave emergence, LHr 
mRNA and 3β-HSD mRNA were found in granulosa cells of only the dominant follicle. The 
dominant follicle of the first follicular wave remains viable for 4 to 5 days, after which most 
mRNAs begin to decline, except for P450arom mRNA which begins to decline 2 days later. If 
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progesterone levels begin to decrease 6 or 7 days after wave emergence, the dominant follicle 
becomes preovulatory and mRNA, except P450arom mRNA, increases [83]. These observations 
could demonstrate that LH pulsatility may be responsible for the expression of steroidogenic 
enzymes mRNA in the granulosa and thecal cells. The notion is supported by the observation 
that mRNA expression is suppressed under low pulsatility of LH observed during the luteal 
phase and increased during the pre-ovulatory increase in LH pulsatility. However, aromatase 
activity is not the rate limiting step in estradiol production. It is the availability of the androgenic 
substrates produced by thecal cells that controls estrogen secretion by granulosa cells (reviewed 
in [80]). 
1.3.3.  Metabolism and elimination of estrogens 
Estrogen bioactivity is also regulated through metabolism and elimination. Estrogens can be 
either inactivated or converted into compounds with lower biological activity before excretion. 
In ruminants, estradiol-17β is in the most part deactivated in the liver by redox reactions 
(oxidation, reduction and hydroxylation) and it is later conjugated with glucuronic or sulphuric 
acid prior to bile excretion. A small amount is also converted into estradiol-17α, which has a 
very low estrogenic activity. In any case, fecal elimination is the most important route of 
excretion, although small amounts of estradiol-17α, and the glucuronide and sulphate conjugates 
can be isolated from the urine [84-86]. 
1.4. Aromatase enzyme 
The aromatase enzyme, also called Aromatase P450 cytochrome enzyme (P450arom), is an 
enzymatic complex that belongs to the super-family of P450 proteins, that includes more than 
480 members divided in 74 different families; P450arom is a unique member of family 19 [87]. 
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This enzyme is located in the endoplasmic reticulum of cells that express the P450arom gene 
(CYP19 gene) such as in adipose tissue, the brain, gonads, fetal tissues, liver and placenta [83, 
88-93]. It is responsible for the conversion of androgens into estrogens in the last step in the 
synthesis of estrogenic compounds. Aromatase enzymes contain a heme group in their structure 
and are functionally associated with another member of P450 cytochrome family, an NADPH 
reductase which acts as a donor of reductive equivalents [92].   
Estrogens are synthesized in all members of the vertebrate phylum [91, 94]. In more 
developed species such as primates, it is synthesized in many different locations in the body such 
as the gonads, adipose tissue, placenta, liver, skin and brain. In ungulates, adipose tissue 
synthesis of estrogens has not yet been fully demonstrated. In rats, the placenta does not have the 
capability to synthesize estrogens [94]. Another characteristic of estrogen synthesis is that 
different tissues can secrete different types of estrogens. For example, the main estrogen 
produced in the ovaries is estradiol, while estrone is synthesized in adipose tissue and estriol 
predominates in the placenta. The aromatase enzyme catalyzing these reactions is the same and 
confirms the idea that the different types of estrogens synthesized in different tissues are not the 
result of the activity of alternative P450arom enzymes, but rather they result from the presence of 
different precursors in each location [94]. 
1.4.1. CYP19 gene: Structure and regulation 
The aromatase gene (CYP19 gene) is a special case of tissue specific regulation of 
transcription by alternative use of different promoters. The gene contains nine exons (from exon 
II to X) that are translated exons. The sequence of ribonucleotides is actually translated in a 
sequence of amino acids in the protein. The exon X has the sequence that encodes the heme 
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binding region and the 3’ untranslated region with alternative poly-adenylation signals. 
Moreover, the gene contains several forms of a first untranslated exon (exon I) located distally 
from the encoding region and is present in the transcripts, but does not encode a sequence of 
amino acids in the aromatase protein [95]. It is estimated that the gene has around 120 kb, where 
30 kb include the translated exons and their introns and about 90 kb contains the alternative 
forms of untranslated exons I and their promoters [87, 89]. Exon I is particular in that it can be 
differentially spliced among several structures located upstream from the translational start site 
(exon II). These structures are alternative forms of exon I which include their own regulatory 
signals and promoter regions and that are activated and spliced out in a tissue specific fashion. 
For instance, in ovaries exon I is spliced out and the transcripts start with exon II. In adipose 
tissue exon I.4 is expressed and in the placenta, exon I.1 is expressed. In cancer-associated 
adipose tissue, exon I.3 and II are expressed [87, 88, 91, 94]. 
After transcription, mRNA undergoes the process of maturation, where introns are spliced 
out and exons are arranged together prior to the initiation of translation. In the case of aromatase 
transcripts, this process is crucial to ensure the translation of the same and unique aromatase 
protein even when the original transcripts differ among tissues [87, 88, 94]. Independent of the 
tissue of origin, every alternative exon I expresses, at the 3’ end of its structure, the same splicing 
donor sequence (GT) that match with the splicing donor sequence (AG) present at the 5’ end of 
exon II. This means that during the process of maturation, exons I are closely attached to exon II, 
regardless of the content or the length of the sequence of ribonucleotides that are between them 
in the heteronuclear mRNA [87, 88, 94]. The mature aromatase mRNA is then translated into a 
sequence of amino acids, starting with the translational start signal (ATG) located within exon II. 
As a result, all the information located upstream from the translation start site is not translated 
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into the polypeptide chain and the final protein is the same in all tissues that have the capability 
to synthesize estrogens. 
1.5. Use of estrogens in food producing animals 
1.5.1. Different applications 
Estrogens and other sex steroids have been developed for use as growth promoter in food 
producing animals, in addition to the previously discussed use of sex steroid hormones as a tool 
for controlling and manipulating reproductive phenomena in cattle and other farm animals [26]. 
The first compound approved by the USA Food and Drug Administration (FDA) to be used as 
growth promoter in beef cattle and sheep was diethylstilbestrol (DES), which has estrogenic 
effects. It was used to improve the efficiency of meat production as well as the proportion of lean 
meat. Since then, several compounds have been formulated and approved for use in farm animals 
including estradiol benzoate, progesterone, testosterone, melengestrol acetate and zeranol, 
among others [26]. Some preparations are still available for oral administration, while others are 
used as subcutaneous implants. The implants may contain single hormones or combinations of 
hormones. Estradiol was believed to be the main growth-promoting compound in combined 
implants and the other hormones used (usually progesterone for steers and testosterone for 
heifers) were included to enhance the anabolic response by either suppressing excessive 
estrogenic stimulation or improving estrogen release from the implant [96]. However, further 
research on the physiologic mechanisms involved revealed that improvements in the anabolic 
effects are due to a additive or synergistic activity of both hormonal compounds contained in the 
implant [26, 27, 96, 97].  
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Growth implants can improve growth rate by 10 to 30% and feed efficiency by 5 to 15% 
[27, 28]. The mechanisms behind this improvement combine the anabolic effects of estrogens 
with the anti-catabolic actions of androgens. Estrogen receptors have been demonstrated in 
striated muscle cells. Further, it was observed that estrogens promote growth-hormone (GH) 
secretion, increase GH receptors in the liver and induce synthesis and secretion of growth factors 
such as IGF-1 from the liver. In addition, androgen receptors were found in the muscles of cattle, 
although in much lower concentrations, and androgenic products can also induce release of GH 
and IGF-1. The reduced glucocorticoid-induced catabolism observed in steers treated with 
androgenic implants may also contribute to the growth-promoting effect [28].  
1.5.2. The issue of estrogens in food: Situation in the European Union, USA and Canada 
There has been an increasing interest of producers on the positive impact of using anabolic 
hormones in meat production systems. However, the potential presence of residues of exogenous 
hormones in meat and other foods originating from treated animals have increased biosafety 
concerns among consumers and scientists [30, 98-100]. The main issues include the involvement 
of naturally occurring hormones and synthetic hormonally active compounds on the development 
of different forms of cancer, abnormal growth of prepubertal children and altered reproductive 
function [32, 99]. While several researchers have attributed carcinogenic effects to estrogens and 
estrogenic compounds (i.e., zeranol), other research groups have failed to replicate those results 
[31, 101].  
The acceptable levels of estrogens and other hormones in food originating from treated 
animals have been under consideration for many years and consensus has not been reached. The 
controversy revolves around acceptable daily intake (ADI) levels, minimum residual levels 
(MRL) and no-observed-effect levels (NOEL) for the different hormones under study [29, 102]. 
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Factors such as method of quantification, age range and physiologic status of the population 
under consideration have made it difficult to determine a common tolerance level for estrogens. 
Further, the impact of the natural occurrence of steroid hormones in food is not completely 
understood [29].  
Despite all the uncertainties around the issue of steroid hormone residue in food originated 
from treated animals, the international situation evolved towards the banning of steroid 
hormones and their synthetic analogs for use in food producing animals in all member states of 
the European Union in January 1989 [103]. The use of E-17β and its ester derivates for 
reproductive management was prohibited on October 14, 2006 [34]. This led to the prohibition of 
the use of estradiol esters in lactating dairy animals in New Zealand and Australia in 2007 [104]. 
The use of estradiol and zeranol (an estrogen-like compound) as growth promoters is still 
permitted in the United States [36] and Canada [37]; however, they can only be applied for the 
purpose of estrus synchronization following prescription and compounding. Compounding has 
recently come under scrutiny in the USA since the FDA declared that it is illegal to compound 
analogs of drugs that are banned to be used in food producing animals, which would be the case 
for E-17β and its derivatives [38, 39].  
1.6. Letrozole 
1.6.1. Classification 
Letrozole [4,4’-(1H-1,2,4-triazol- 1-yl-methylene)-bis-benzonitrile] is a type II, very potent 
non-steroidal aromatase inhibitor. Its chemical structure contains a triazole group (Fig. 1.2) that 
selectively interacts with the heme group of the P450arom enzyme, thereby reversibly inhibiting 
the bioactivity of the enzyme [105-107]. Letrozole is highly selective for P450arom blocking only 
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estrogen production without altering progesterone or corticosteroid synthesis [108, 109]. In 
North America, letrozole is marketed under the name of FEMARA® (Novartis) and it is 
approved for the treatment of estrogen-dependent breast cancer in postmenopausal women. 
 
Fig.1.2. Chemical structure of letrozole: its chemical structure contains a triazole group that 
selectively binds to the heme group of the aromatase enzyme 
 
1.6.2. Pharmacology of letrozole in humans 
The pharmacokinetics of letrozole in humans have been described in several studies 
conducted on healthy post-menopausal women, breast cancer patients, and in healthy male 
volunteers [109-112]. It was reported that letrozole is rapidly and completely absorbed after oral 
administration  [111] and its half-life is approximately 42 hours in healthy subjects [111, 112] 
and 82 hours in breast cancer patients [110]. Breast cancer patients also have been shown to have 
higher area under the curve (AUC) values than healthy individuals which may suggest a reduced 
metabolic clearance and consequently a lower elimination rate [110]. Approximately 60% of 
letrozole found in circulation is bound to plasma proteins, mainly albumin [111, 112]. Letrozole 
is eliminate mainly via metabolism by P-450 isozymes (CYP3A4 and CYP2A6) into a 
pharmacologically inactive alcohol metabolite [110, 111]. The main route of excretion of 
letrozole is urine, where 6.8% of the given dose of letrozole was found unchanged [110]. 
A pharmacodynamic study of letrozole in healthy postmenopausal women in which three 
different doses of letrozole were used revealed maximal suppression of serum estradiol of 
76.5%, 78.5% and 78.8% from baseline at 72 hours post-treatment with 0.1, 0.5 and 2.5 mg of 
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letrozole given in a single dose, respectively [113]. In postmenopausal breast cancer patients, in 
vivo aromatization and plasma estrogen levels were measured after 0.5 or 2.5 mg of letrozole 
given daily for at least 6 weeks. Letrozole inhibited aromatase activity by 98.4% and >98.9%, 
respectively. Plasma estradiol concentrations were reduced by 84.1% and 68.1%, respectively 
[114]. In a trial conducted in healthy male volunteers, estradiol suppression was about 30% at the 
lowest dose (0.02 mg) and 80-90% at the highest dose (30mg) tested [109].  
1.6.3. Uses of letrozole in cancer therapy 
Seventy-five percent of women suffering from breast cancer have hormone receptor positive 
(+) disease [115]. This means that circulating hormones, mainly estrogens and progesterone, 
stimulate the division and growth of the tumour tissue. It was observed that the surgical removal 
of the ovaries (ovariectomy) was effective in reducing tumor size and survival rates of non-
operable breast cancer patients more than 100 years ago [116]. Years later, this was attributed to 
estrogen deprivation. However, there were some limitations to the massive use of ovariectomy. 
Firstly, it is a very invasive and non-conservative procedure to be performed, especially in young 
patients wishing to conceive after treatment. Secondly, after natural menopause or ovariectomy, 
peripheral production of estrogens, mainly by adipose tissue, contributes importantly to the total 
circulating levels of estrogen [117]. Therefore, several systemic methods of treatment have been 
developed to reduce the effects of estrogens (of any source) on breast cancer growth either by 
irreversibly binding to tumour-estrogen receptors (antiestrogens) or inhibiting estrogen synthesis 
at the enzymatic level (aromatase inhibitors) [118]. In 1998, letrozole was approved as second-
line treatment. In January 2001, letrozole was approved as a first-line treatment for breast cancer 
in post-menopausal women by the FDA [119, 120]. Because of its potent inhibition of estradiol 
production, high oral bioavailability, selectivity and mild secondary effects, letrozole has become 
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a drug of preference for the treatment of breast cancer, either as a first-line treatment or as a 
neoadjuvant therapy [40, 117, 121].  
Letrozole has also been proposed for the treatment of endometrial cancer and endometriosis 
[122, 123]. Both pathologic conditions are steroid hormone-responsive; therefore, letrozole and 
other aromatase inhibitors could be beneficial and promising results have already been reported 
[124-126].   
1.6.4. Letrozole in the treatment of infertility in women 
Commercially available letrozole (FEMARA
®
) is not labelled for use in any pathologic 
condition other than hormone-dependent breast cancer in post-menopausal women [40, 127]; 
however there are numerous reports on the use of letrozole for the treatment of subfertility or 
infertility in women undergoing ovarian superstimulation, intra-uterine insemination (IUI) or 
timed intercourse [123, 128, 129]. Although the effects of estrogen deprivation on the 
reproductive physiology of premenopausal women are not completely elucidated, letrozole has 
been used in assisted reproduction because of its apparent effect of removing the negative 
feedback effects of estradiol on gonadotrophin secretion. Theoretically, removal of circulating 
estradiol should be followed by a surge in FSH levels and this would induce the recruitment of a 
new wave of follicular development, the final maturation of the oocyte or even the development 
of more than one ovarian follicle [41, 42]. Letrozole has been used alone as a single or a 5-day 
regimen for ovarian stimulation [42, 130, 131], and in higher or increasing doses to induce 
ovarian superstimulation in women [46, 47]. Letrozole has also been used in combination with 
gonadotrophin treatment for ovarian superstimulation prior to IUI. Improvements in the ovarian 
response of poor responders and a significant decrease in the dose of FSH required to achieve an 
acceptable stimulatory response have been reported [44, 132].  
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1.6.5. Letrozole toxicity 
Letrozole has proven to be a well tolerated drug, lacking of toxic effects when used as 
indicated for breast cancer treatment in post-menopausal women. Toxicity studies performed for 
the approval of FEMARA® concluded that repeated dosing caused sexual inactivity in females 
and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1 and 0.03 mg/kg in 
mice, rats and dogs, respectively. Although all the reported toxic effects of letrozole have been 
observed during long-term treatment (as those used for breast cancer therapy), less is know about 
its toxic effects when used in a short-term treatment for ovarian stimulation. Letrozole is 
classified as embryotoxic, and it is contraindicated in premenopausal and pregnant women [40]. 
In 2005, the safety of letrozole as a treatment for ovulation induction was seriously 
challenged by a abstract published by Biljan et al. [133]. In that retrospective study, the authors 
reported an increased risk for congenital cardiac and bone malformations related to the use of 
letrozole as an infertility treatment. However, the scientific credibility of that study was strongly 
questioned based on the number of letrozole-treated cases reported versus the control cases (150 
vs 36,050 babies, respectively) and the inadequacy of the comparison made among these groups. 
Shortly thereafter, another retrospective study reported the absence of teratogenic effects of 
letrozole when used as an ovulation induction therapy [134]. Recently, a prospective trial was 
designed to evaluate pregnancy outcomes after ovarian stimulation with aromatase inhibitors. 
The conclusions drawn from this study further confirmed the safety of aromatase inhibitor as a 
tool for infertility management in women [135]. 
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1.7. The bovine model for the study of human reproduction 
Based on the similarities between cattle and women regarding ovarian size, follicular size 
and endocrine regulation of the follicular development, and because of the accessibility and 
adaptability of the bovine species, a bovine model has been validated as a tool to assess and 
further investigate human reproductive physiology [49, 136-140]. The description of a wave-like 
pattern of follicular growth during the estrous cycle in women, as observed in other mammals 
(cow, mare, sheep) [49, 140], represented a break-through discovery. Two or three waves of 
follicular development were observed during the follicular as well as the luteal phase of the 
estrous cycle in healthy female volunteers [138]. It was also shown that the wave-like pattern 
observed was controlled by the same endocrine mechanisms as described in other monovulatory 
species such as cattle [137]. Consequently, the bovine model has been successfully implemented 
for the study several features of human reproduction including ovarian senescence [141] and 
oocyte competence after reproductive aging [142]. Therefore, it is plausible that the bovine 
model could be used to elucidate the effects of letrozole on ovarian function in premenopausal 
women and to further understand and explore its potential as a treatment for ovarian stimulation.  
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2. GENERAL HYPOTHESIS 
The overall hypothesis tested in this thesis was that letrozole given as a single or multiple-
dose treatment would reduce estradiol production and thus circulating estradiol concentrations. 
Releasing the pituitary gland from the negative feedback effect of estrogens would elicit a surge 
in FSH secretion, thus inducing the emergence of a new follicular wave.  
 
3. GENERAL OBJECTIVES 
The overall objectives of the studies reported herein were to determine the effects of an 
aromatase inhibitor on endocrine function and follicular dynamics in cattle, and to determine a 
minimum effective dose of letrozole treatment to predictably induce these changes. In the first 
experiment, the effect of three different doses of letrozole administered as a single intravenous 
injection on hormonal profiles and ovarian function were compared to a control group. In the 
second experiment, the effects of a 3-day treatment regimen of letrozole given at three different 
stages of follicular development on hormonal profiles and ovarian function were compared to 
their respective non-treated controls. It was hypothesized that the stage of follicular development 
would not alter the ovarian response to letrozole treatment. 
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4. EFFECTS OF LETROZOLE ON OVARIAN FUNCTION IN CATTLE 
4.1. Abstract 
An experiment was designed to determine the effects of a non-steroidal aromatase inhibitor, 
letrozole, on ovarian function in cattle. The specific objectives were to test the hypothesis that 
letrozole will arrest growth of the dominant follicle resulting in emergence of a new follicular 
wave at a predictable interval post-treatment. Beef heifers were assigned randomly to four 
treatment groups and given phosphate-buffered saline (controls; n=10), or letrozole at a dose of 
500 (n=9), 250 (n=10), or 125 (n=10) µg/kg intravenously 4 days after follicular ablation (~2 ½ 
days after wave emergence). Blood samples were collected and ovarian structures were 
monitored daily by transrectal ultrasonography. The diameter profile of the dominant follicle was 
larger in heifers treated with letrozole than in control heifers (P<0.05). The intervals from 
treatment to new wave emergence and from treatment to onset of regression of the extant 
dominant follicle were longer (P<0.05) in heifers treated with letrozole than in controls, although 
variances in the intervals were not different. A small but significant reduction in circulating 
estradiol concentrations was observed, and plasma LH concentrations were higher (P<0.05) in 
letrozole-treated heifers than in controls. Lower plasma concentrations of FSH in letrozole-
treated heifers than in controls (P<0.03) were interpreted as an indirect effect resulting from 
prolonged follicular dominance. In summary, a single dose of letrozole did not induce regression 
of the extant dominant follicle, nor did it directly affect FSH release. Conversely, letrozole 
extended the lifespan of the dominant follicle, in association with increased endogenous levels of 
LH, thereby delaying the next FSH surge and subsequent follicular wave emergence. Results 
suggest that letrozole has potential as a non-steroidal method for controlling ovarian function in 
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cattle, but further studies are warranted to clarify mechanism of action, dosage and timing of 
treatment.  
4.2. Introduction  
Among the strategies used to control ovarian function in cattle, treatment with estrogen in 
combination with progesterone has been very effective for synchronizing follicle wave 
emergence and ovulation [9, 21]. Steroid-induced wave synchronization is brought about by 
regression of the dominant follicle followed by resurgence in circulating FSH and subsequent 
emergence of a new follicular wave at a consistent interval post-treatment. Steroid-induced 
regression of the dominant follicle is a result of a systemic alteration in feedback of estradiol and 
progesterone on pituitary release of LH and FSH [10]. Estradiol suppresses FSH release [11], 
and decreases LH pulse amplitude in sheep [12] and cattle [13]. Progesterone decreases LH pulse 
frequency and suppresses growth of the dominant follicle in a dose-dependent manner in cattle 
[14-19]. After metabolic clearance of exogenous estradiol, endogenous FSH surges therefore 
resulting in the emergence of a new wave of follicular development approximately 4 days after 
estradiol/progesterone treatment regardless of the stage of development of the dominant follicle 
at the time of treatment [9, 20, 21]. The degree of synchrony achieved with protocols involving 
estradiol and progesterone has permitted effective use of fixed-time artificial insemination in 
cattle [22, 23, 77], as well as more efficient use of time and labour for multiple ovulation and 
embryo transfer and conventional breeding management programs [9, 10].  
The use of natural or synthetic estrogens in food producing animals, however, has been the 
subject of considerable controversy (reviewed in [32]). Increasing concern regarding the toxicity 
of hormonal preparations used as growth promotants in cattle and the potential carcinogenic 
effects of steroid hormone residues in meat or milk [29-31] has led to a prohibition of the use of 
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estradiol and other steroid hormones as growth promotants in animals designated for human 
consumption in all the member states of the European Union as of January 1, 1989 [33]. 
Furthermore, the use of estradiol-17β and its ester derivatives for purposes of reproductive 
management was prohibited in the European Union on October 14, 2006 [34]. These actions in 
Europe led to the subsequence prohibition of the use of estradiol esters in lactating dairy animals 
in New Zealand and Australia in 2007 [104]. Although the use of estradiol and zeranol (an 
estrogen-like compound) as growth promotants is still permitted in the United States [36] and 
Canada [37], they cannot be used for the purpose of estrus synchronization except by 
prescription and custom-compounding. However, veterinary compounding of pharmaceuticals 
for food-producing animals has recently come under scrutiny in the US and is discouraged [38, 
39]. This situation negatively impacts the implementation of reproductive technologies in cattle 
production systems, limiting potential reproductive efficiency and genetic improvement provided 
by the use of artificial insemination and embryo transfer [104].  
In this context, the development of alternative methods for controlling ovarian function in 
cattle, with no toxic or harmful effects on human or animal health, are needed. Aromatase 
inhibitors prevent the body from producing its own estrogens. Therefore, we proposed that 
aromatase inhibitors may be an effective alternative to control ovarian follicular development in 
cattle. Letrozole, a non-steroidal aromatase inhibitor, inactivates the aromatase enzyme by 
reversibly binding to the heme group of the P450 subunit of the aromatase enzyme. Letrozole is 
used as an adjuvant treatment for hormone-responsive breast cancer in post-menopausal women 
[40], and has been used as a fertility therapy for women undergoing assisted reproduction 
because of its putative effect on FSH secretion through removal of the negative feedback of 
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estradiol [41]. A 5-day regimen of letrozole has been used for ovarian stimulation in women 
[42], and in higher or increasing doses to induce ovarian superstimulation in women [46, 47].  
In an effort to develop an effective, safe, and steroid-free protocol for controlling ovarian 
follicular wave dynamics in cattle, the specific objectives of this experiment were to gain an 
understanding of the effects of an aromatase inhibitor (letrozole) on bovine ovarian function and 
to establish a minimum effective dose of letrozole in cattle. We tested the hypothesis that 
letrozole will terminate growth of the extant dominant follicle and result in a surge in circulating 
FSH concentrations followed by the emergence of a new wave of follicular growth at a 
predictable interval post-treatment. 
4.3. Materials and Methods  
4.3.1. Cattle 
Hereford-cross beef heifers, 14 to 20 months of age and weighing between 295 and 450 kg, 
were chosen from a herd of 50 heifers maintained in outdoor corrals at the University of 
Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers were fed alfalfa/grass 
hay and grain to gain approximately 1.3 Kg per day and had water ad libitum during the 
experimental period from July to October. Heifers were initially examined by transrectal 
ultrasonography (7.5 MHz linear-array transducer, Aloka SSD-900; Tokyo, Japan) to confirm 
that they were postpubertal by observing the presence of a CL [143]. 
4.3.2. Treatments and examinations 
Heifers in which a CL was detected during the initial examination were given 500 µg of 
cloprostenol (PGF, Estrumate
TM
, Schering-Plough Animal Health, Pointe-Claire, QC, Canada) 
intramuscularly (im) to induce regression of the CL and to synchronize ovulation [144]. Heifers 
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were examined daily by transrectal ultrasonography to detect ovulation. Transvaginal ultrasound-
guided follicular aspiration of follicles ≥5 mm was performed five to eight days after ovulation 
to synchronize wave emergence [145]. Heifers were examined daily by transrectal 
ultrasonography to detect follicular wave emergence, which was expected 1 to 1.5 days after 
follicular ablation [145]. Four days after follicular ablation (approximately 2.5 days after 
follicular wave emergence), and at the time follicular dominance becomes apparent [57], heifers 
were assigned randomly to the following treatment groups and given a single intravenous dose of 
1) 500 µg/kg of letrozole (high dose group, n=9), 2) 250 µg/kg of letrozole (medium dose group, 
n=10), 3) 125 µg/kg of letrozole (low dose group, n=10), or 4) 20 ml of phosphate buffered 
saline (PBS control group, n=10). For practical purposes, the dose of letrozole was calculated 
based on an average weight of 400 kg for all heifers. The average oral dose used in women (2.5 – 
5 mg per day for 5 days) was used to estimate the medium dose for cattle [41, 42]. The high and 
low doses were set as double and half the medium dose, respectively. The day of treatment was 
defined as Day 0. For intravenous injection, letrozole was prepared in 95% ethanol at a final 
concentration of 5 mg per ml, resulting in an injection volume of 10 - 40 ml. The experiment was 
performed in four replicates (n=2-3 per group per replicate) and each heifer was used only once. 
4.3.3. Ovarian ultrasonography 
The observations from ultrasound examination were recorded on a sketch sheet in which 
each ovary and its structures (CL and follicles ≥ 4 mm in diameter [54]) were represented in size 
and location. Ovulation was defined as the disappearance of any follicle ≥8 mm between two 
consecutive daily examinations, and was confirmed by the subsequent development of a CL 
[143]. Follicular wave emergence was defined retrospectively as the day when the dominant 
follicle was first identified at a diameter of 4 or 5 mm [48, 57]. If the dominant follicle was not 
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identified until it reached 6 or 7 mm, the previous day was considered day of the follicular wave 
emergence [66]. The dominant follicle of a wave was defined as the largest antral follicle of that 
wave after deviation, and the first subordinate follicle as the second largest antral follicle of that 
wave [146]. The day of onset of follicular and luteal regression was defined as the first day of an 
apparent constant decrease in follicular  and luteal diameters, respectively [57]. 
4.3.4. Collection of blood samples 
Blood samples were collected by jugular or coccygeal venipuncture into 10 ml heparinized 
vacuum tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Blood samples 
were collected at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post-treatment [111] using 
an indwelling jugular catheter as previously described [63] and daily thereafter to the first post-
treatment ovulation. Blood samples were centrifuged at 1500 x g for 20 minutes; plasma was 
separated and stored in plastic tubes at -20 °C. 
4.3.5. Hormone assays 
Plasma LH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay (NIDDK-bLH4) [12, 147]. The minimum and maximum values along the 
standard curve were 0.06 and 8 ng/mL, respectively. The intra- and inter-assay coefficients of 
variation were 10.2% and 8.8%, respectively, for low reference samples (mean, 0.88 ng/mL) and 
9.4% and 9.1%, respectively, for high reference samples (mean, 2.7 ng/mL).  
Plasma FSH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay using NIDDK-anti-oFSH-1 primary antibody and expressed as USDA bovine 
FSH-Il units [12, 147]. The minimum and maximum values along the standard curve were 0.12 
and 16 ng/mL, respectively. The intra- and inter-assay coefficients of variation were 11.2% and 
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10.0%, respectively, for low reference samples (mean, 1.7 ng/mL) and 12.0% and 12.4%, 
respectively, for high reference samples (mean 4.4 ng/mL).  
Plasma estradiol concentrations were determined in duplicate by enzyme-linked 
immunosorbent assay (Cayman Chemical Company, Ann Arbor, MI, USA). In this competitive 
ELISA, plasma steroid competes with acetylcholinesterase-labelled steroid for the binding site 
on polyclonal rabbit anti-steroid antibody. The antiserum to estradiol was reported to cross-react 
with estradiol-3-glucoronide (14%), estrone (12%), and estriol (0.3%). For all other steroid 
hormones, cross-reactivity was reported as <0.1%. The minimum and maximum values along the 
standard curve were 6.6 and 4000 pg/well, respectively. The intra- and inter-assay coefficients of 
variation were 11.7% and 12.7%, respectively, for reference samples analyzed in duplicate. A 
concentration procedure using diethyl ether extraction was performed prior to the assay in all 
samples to increase estrogen concentration to measurable levels [148] . A 
3
H-labeled steroid was 
added to each plasma sample before extraction as an internal recovery standard. After the 
extraction procedure, a fraction of the final extract was quantified in a liquid scintillation counter 
to test for recoveries [149]. To confirm the effectiveness of the ELISA in quantifying estradiol 
concentrations in plasma, a random sub-set of plasma samples (n=25) was also analyzed by high 
performance liquid chromatography mass spectrometry (LC/MS) and results were compared to 
those obtained by ELISA (Appendices 3 and 4). 
4.3.6. Plasma letrozole concentration 
Plasma concentrations of letrozole were determined using high performance liquid 
chromatography tandem mass spectrometry (LC/MS/MS). To extract letrozole from the samples, 
250 µL of a buffer solution (0.1 M ammonium) were added to 250 µL of plasma followed by the 
addition of 5 mL of methyl t-butyl ether (MTBE) and vortexed for 15 sec. The organic layer was 
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removed by pipetting and transferred to a fresh 15 mL plastic tube. This second tube was dried 
by gentle nitrogen gas flow. The dried extract was reconstituted in 1 mL of 100% ethanol, 
sonicated for 5 min and transferred to a labelled vial for further analysis. Separation was 
accomplished by HPLC (Agilent 1200, Santa Clara, CA, USA) fitted with an analytical column 
(50x2.1 mm, 3 µm particle size; Thermo Scientific Betasil C18, Waltham, MA, USA) operated 
at 35ºC. Gradient conditions were used at a flow rate of 250 µL/min, starting at 85% A (0.1% 
acetic acid) and 15% B (0.1% acetic acid in acetonitrile). Initial conditions were held for 2 min 
and then ramped to 100% B at 6 min, held until 9 min, decreased to 0% B at 11 min, and 
returned to initial conditions at 13 min, and held constant until 15 min. Mass spectra were 
collected using a tandem mass spectrometer (Applied Bioscience SCIEX 3000, Foster City, CA, 
USA) fitted with an electrospray ionization source, operated in the negative ionization mode. 
Chromatograms were recorded using multiple reaction monitoring (MRM) mode, where at least 
two transitions per-analyte were monitored. The following instrument parameters were used: 
desolvation temperature 450ºC, desolvation (curtain) gas 6.0 arbitrary units (AU), nebulizer gas 
flow 4 AU, ion spray voltage 4500 V, collision gas 12 AU, collision energy 46 AU, declustering 
potential 30 AU, and a dwell time of 100 msec. Quantification using these transitions was 
performed using Analyst 1.4.1 software provided by SCIEX (Applied Bioscience, Foster City, 
CA, USA). The minimum and maximum values along the standard curve were 0.25 and 500 
µg/mL respectively. The limit of quantification used in this method was 250 ng/L and the mean 
recovery was 70%. The plasma letrozole concentration vs. time (C–t) data for each heifer was 
analyzed by non-compartmental techniques using a computer modeling program (WinNonLin 
Standard Edition Version 2.1, Pharsight Corporation, Mountain View, CA, USA). Peak 
concentration in plasma (Cmax) and time to peak concentration (tmax) were determined using 
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observed values. The apparent terminal rate constant (λ) was determined by linear regression of 
the last 6–8 points on the terminal phase of the logarithmic plasma concentration vs. time curve. 
The area under the C–t curve until the final plasma sample (AUClast) was determined using the 
linear trapezoidal rule. The total area under the curve extrapolated to infinity (AUC0-∞) was 
calculated by adding the Clast obs/λ + AUClast. The terminal half-life (T1/2λ) was calculated as ln2 
⁄λ. The mean residence time (MRT) was calculated as the area under the moment curve 
extrapolated to infinity (AUMC0-∞) ⁄AUC0-∞. Systemic clearance (ClS) was determined using the 
dose divided by AUC0-inf. The apparent volume of distribution (Vλ/f) was calculated by clearance 
divided by λ.  
4.3.7. Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series hormone data, 
plasma letrozole concentration, and follicular diameter profiles were analyzed by repeated 
measures, using the PROC MIXED procedure. The main effects were treatment (high, medium 
and low dose, and control), time, and their interactions. When no differences were detected 
among doses of letrozole, data were combined and re-analyzed as a single letrozole treatment 
group. Single point measurements (intervals from ablation to wave emergence, treatment to wave 
emergence, treatment to ovulation, treatment to onset of follicular regression, and treatment to 
onset of CL regression) were analyzed by one-way analysis of variance. Paired t-test was used to 
compare estradiol concentration pre- and post-treatment within a treatment group and two-
sample t-test was used to compare estradiol concentration at a single data point between letrozole 
and control groups. An F-test was used to analyse if the variability in the interval from treatment 
to wave emergence was significantly different between letrozole-treated and control heifers. Due 
36 
 
to individual variability in circulating concentrations of LH and FSH among heifers, and because 
our objective was to determine the effect of treatment within individuals, LH and FSH data were 
transformed to a percentage of the mean concentration of the first three samples (i.e., 0, 15, and 
30 min post-treatment) for each individual heifer. Residuals from percent data were normally 
distributed, therefore, transformation of percent data was not required. All values are expressed 
as mean ± SEM. 
Animal procedures were performed in accordance with the Canadian Council on Animal 
Care and were approved by University of Saskatchewan Protocol Review Committee. 
4.4. Results 
4.4.1. Ovarian function 
The interval from follicular ablation to emergence of the new follicular wave did not differ 
among treatment groups (1.7, 1.6, 1.7 and 1.6 days for high-, medium- and low-dose letrozole, 
and control groups, respectively). Consequently, treatment was applied 2.4 ± 0.1 days after 
follicular wave emergence, when the growing dominant follicle was 7.1 ± 0.3 mm. The interval 
from ablation to treatment, and the diameter of the dominant follicle at the time of treatment did 
not differ among groups.  
Although the dominant follicle diameter profiles after letrozole treatment followed a dose-
dependent pattern, differences among the letrozole dose groups were not significant (P=0.11, 
Appendix 1). Therefore, data from all letrozole dose groups were combined for comparison with 
the control group. The dominant follicle diameter profile of letrozole-treated heifers was larger 
(P<0.04) than that of control heifers (Fig 4.1). The dominant follicle grew to a larger diameter 
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(11.0 ± 0.32 vs 9.7 ± 0.55 mm) and regressed later (P<0.05; Table 1) in letrozole-treated heifers 
with than in control heifers.   
 
 
Figure 4.1. Diameter profile (mean ± SEM) of the dominant follicle in heifers treated with 
letrozole (high-, medium- and low-dose groups combined; n=29) 4 days after follicular ablation 
(i.e., 2.5 days after wave emergence), compared to saline-treated controls (n=10).  
 
The number of heifers in which the extant dominant follicle (i.e., the dominant follicle 
present at the time of treatment) ovulated did not differ among groups (5/9, 5/10, 7/10 and 4/10 
heifers in high-, medium-, low-dose and control groups, respectively), but the interval to 
ovulation was longer in letrozole-treated heifers compared to controls (Table 4.1). In heifers that 
did not ovulate the extant dominant follicle, the intervals from treatment to onset of dominant 
follicle regression and to emergence of a new follicular wave were longer in those treated with 
letrozole than in controls (P<0.05; Table 4.1). The variability (degree of synchrony) in intervals 
from treatment to wave emergence or dominant follicle regression was not different between 
letrozole-treated and control groups (F-value=2.7, P>0.05). 
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Table 4.1. Effects of letrozole on interval to follicle wave emergence, ovulation, onset of 
follicular regression and onset of CL regression in cattle. Data from low-, medium- and high-
dose treatment groups were combined, and compared to saline-treated controls. Values are 
expressed as mean ± SEM. 
Intervals (days) Letrozole Control 
Treatment to wave emergence* 
7.5 ± 0.27 
a 
(n=29) 
5.9 ± 0.46 
b
 
(n=10) 
Treatment to ovulation of extant dominant follicle** 
9.0 ± 0.42 
a 
(n=16) 
8.0 ± 0.86 
a 
(n=4) 
Treatment to onset of regression of extant dominant 
follicle** 
8.7 ± 0.47 
a 
(n=13) 
5.2 ± 0.65 
b 
 (n=6) 
Treatment to onset of CL regression 
6.1 ± 0.35 
a 
(n=29) 
5.1 ± 0.62 
a 
(n=10) 
ab
 Within rows, values with different superscripts are different (P<0.05) 
*Differences in variability between groups were not significant 
**Dominant follicle present at the time of treatment 
 
4.4.2. Circulating hormone concentrations 
Plasma FSH concentrations during the 4 days after treatment were not different among 
letrozole-dose groups; hence, data were combined for comparison with saline-treated controls.  
Plasma FSH levels tended to increase in both letrozole and control groups, but proportionately 
less in the letrozole-treated animals (Fig. 4.2). By 72 hours after treatment, plasma FSH 
concentrations were lower in heifers treated with letrozole than in controls (P<0.03).  
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Figure 4.2. Plasma FSH concentrations (percent change after treatment; mean ± SEM) in heifers 
treated with letrozole (high-, medium- and low-dose groups combined; n=29,) 4 days after 
follicular ablation (i.e., 2.5 days after wave emergence), compared to saline-treated controls 
(n=10).  
 
Plasma LH concentrations during the 12-hour period after treatment did not differ among 
letrozole-treated groups; hence, data were combined for comparison with PBS-treated controls. 
Heifers treated with letrozole had higher plasma LH concentrations than saline-treated controls 
during the first 12 hours following treatment (P=0.05; Fig. 4.3). Similarly, plasma LH 
concentrations during the 4-day period after treatment were not different among letrozole-treated 
groups and after combining data, heifers treated with letrozole had higher plasma LH 
concentrations than saline-treated controls (P=0.01; Fig. 4.3).  
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Figure 4.3. Plasma LH concentrations in heifers (percent change after treatment; mean ± SEM) 
during the first 12 hours (left) and for 96 hours (right) after a single intravenous dose of letrozole 
(high-, medium- and low-dose groups combined; n=29) given 4 days after follicular ablation 
(i.e., 2.5 days after wave emergence), compared to saline-treated controls (n=10). 
 
Plasma estradiol concentrations did not differ among the letrozole-treated groups; hence, 
data were combined for comparison with saline-treated controls. Mean plasma concentrations of 
estradiol over the 4-day period after treatment tended to be higher in letrozole-treated heifers 
compared to control heifers (P=0.06), primarily as a result of an increase between 4 and 12 hours 
after treatment in letrozole-treated heifers (Fig. 4.4). Plasma estradiol concentrations decreased 
by nearly 50% from 0 to 24 hours after treatment in letrozole-treated heifers (from 15.2 ± 3.01 to 
8.0 ± 1.51 pg/mL; P=0.03) while no change occurred in control heifers (from 11.0 ± 3.16 to 12.1 
± 3.43 pg/mL, P=0.72).  
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Figure 4.4. Plasma estradiol concentrations (mean ± SEM) in heifers during the first 96 hours 
after a single intravenous dose of letrozole (high-, medium- and low-dose groups combined; 
n=29) given 4 days after follicular ablation (i.e., 2.5 days after wave emergence), compared to 
PBS-treated controls (n=10). Within groups, differences in estradiol concentrations between 0 
and 24 hours after treatment were compared by paired t-test.  
*Values differed between groups (P<0.03).  
     
4.4.3. Plasma letrozole concentration 
Plasma letrozole concentrations, as determined by LC/MS/MS, followed a dose-dependent 
pattern (Fig. 4.5). Mean plasma concentrations throughout the 8-day period were 0.63 ± 0.04 
µg/mL, 0.44 ± 0.04 µg/mL, and 0.27 ± 0.04 µg/mL for high-, medium- and low-dose groups, 
respectively (P<0.0001). Pharmacokinetic parameters are summarized in Table 4.2. No 
significant differences were detected among dose-groups in the half-life (T1/2), volume of 
distribution (Vz/f), systemic clearance (ClS) and mean residence time (MRT). Maximal 
concentration (Cmax) and area under the curve (AUClast) differed between high, medium and low 
doses following a dose-dependent pattern (P=0.007 and P<.0001, respectively). 
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Figure 4.5. Plasma letrozole concentration (mean ± SEM) as determined by HPLC/MS after 
administration of a single intravenous dose of 125, 250, or 500 µg/kg. Data from Hour 0 to 12 
hours after treatment are depicted. 
 
Table 4.2. Pharmacokinetics of letrozole after administration of a single intravenous dose of 125, 
250, or 500 µg/kg in postpubertal beef heifers, determined by non-compartmental analysis (mean 
± SEM). 
Parameter 
125 µg/kg 
(n=9) 
250 µg/kg 
(n=9) 
500 µg/kg 
(n=9) 
Combined 
Maximal concentration (Cmax) 
(µg/mL) 
1.2 ± 0.25
a 
1.7 ± 0.18
b 
2.5 ± 0.37
c 
1.8±0.27 
Half-life (T1/2) (hours)  26.9 ± 0.95
a 
26.6 ± 1.18
a 
28.5 ± 1.05
a 
27.3 ± 0.42 
Area under the curve (AUClast) 
(hours x µg/mL) 
8.8 ± 0.72
a 
17.3 ± 2.00
b 
28.1 ± 2.15
c 
18.2 ± 4.03 
Volume of distribution (Vz/f) 
(mL/kg) 
566.2 ± 43.95
a 
592.9 ± 66.06
a 745.7 ± 
47.35
a 634.9 ± 39.54 
Systemic clearance (ClS) 
(mL/hour/kg) 
14.6 ± 1.10
a 
15.5 ± 1.75
a 
18.5 ± 1.67
a 
16.2 ± 0.83 
Mean residence time (MRT) 
(hours) 
31.7 ± 2.00
a 
33.7 ± 2.98
a 
35.8 ± 1.43
a 
33.7 ± 0.84 
abc
 Within rows, values with no common superscript are different (P < 0.05) 
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4.5. Discussion 
Letrozole has been used for several years for ovarian stimulation and induction of ovulation 
in women [42-47, 128-130, 132, 150]; however, there are apparently no reports on the use of 
letrozole to control ovarian function in cattle. Based on clinical observations resulting from 
infertility treatments in women, it was hypothesized that letrozole would induce a drop in 
circulating E-17β concentrations followed by an increase in concentrations of FSH which would 
trigger the emergence of new follicular development [42, 43]. However, results of the present 
study in cattle did not support this hypothesis. On the contrary, a single treatment with letrozole 
on Day 3 post-ovulation in cattle, regardless of the dose, significantly lengthened the period of 
dominance of the extant dominant follicle, resulting in a prolonged interval to emergence of a 
new follicular wave. Furthermore, the mean diameter achieved by the dominant follicle was 
significantly larger in letrozole-treated heifers. Letrozole treatment was associated with elevated 
plasma LH concentrations, but had no apparent effect on FSH concentrations.  
Mean plasma estradiol concentrations in letrozole-treated heifers tended to be higher than in 
controls for the first 4 days after treatment, but this was attributed primarily to a significant and 
sharp elevation at 12 hours after letrozole treatment. This acute elevation in estradiol has not 
been reported in women, but a similar increase was observed in rats, and was interpreted as the 
result of a gonadotrophin release caused by letrozole treatment [151]. Although in the present 
study plasma estradiol concentrations decreased by nearly 50% by 24 hours after letrozole 
treatment, concentrations were not significantly lower than controls.  
The lack of an apparent suppressive effect of letrozole on estrogen concentrations in cattle in 
the present study may have been the result of insufficient assay sensitivity and/or an inadequate 
dose of letrozole. In women, basal and maximum circulating estradiol concentrations have been 
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reported to be approximately 20 and 200 pg/mL, respectively [137]. In the heifers examined in 
this study, basal plasma estradiol concentrations were below the detection limit (3 to 4 pg/mL) 
and, on average, maximum concentrations did not exceed 25 pg/mL during the first 8 days after 
ovulation. In addition, the dose and duration of letrozole treatment used in our experiment may 
not have been sufficient to inhibit estradiol production in cattle, in contrast to other species in 
which treatment resulted in a marked reduction in circulating estradiol concentrations (97-99% in 
post-menopausal women [42], and 88% in boars [152]). 
Extended growth and delayed regression of the extant dominant follicle was attributed to 
letrozole-induced elevation in plasma LH concentrations [15, 18]. Endogenous concentrations of 
LH began to rise 2 hours after letrozole was administered and levels were elevated for at least 4 
days after treatment. Increasing concentrations of LH during this time may also have elicited the 
surge in plasma estradiol concentrations observed 12 hours post-treatment. 
Contrary to our expectations, plasma FSH concentrations were lower in letrozole-treated 
heifers than in controls. Follicular products other than estradiol also suppress FSH and may be 
responsible for the effect observed [3, 153, 154]. Inhibin is secreted by the dominant and 
subordinate follicles during the time of follicular deviation and, together with estradiol, has been 
associated with the suppressive effects involved in follicular selection and dominance [139, 155]. 
However, letrozole treatment in the present study was associated with over-dominance 
(prolonged growth and maintenance of the dominant follicle) resulting in an extended period of 
FSH suppression and delayed emergence of the next follicular wave. It is noteworthy that 
inhibition of estradiol synthesis by an aromatase inhibitor did not adversely affect the extant 
dominant follicle, rather it indirectly enhanced follicular dominance by permitting elevated 
pituitary LH secretion.  
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Although most of the studies in women in which letrozole was used to treat unexplained 
infertility are based on a 5-day treatment regimen (total dose of 12.5 to 20 mg letrozole), single 
dose treatments of 20 mg administered orally on the third day of the menstrual cycle have been 
reported to be equally effective in suppressing circulating estrogen concentrations. The half-life 
of letrozole in humans has been reported to be approximately 2 days which could result in 
effective suppression of estradiol production for 4 to 6 days after a single administration [130]. 
Although the pharmacokinetic parameters reported in the present study are preliminary, we 
estimated the half-life of letrozole in heifers to be 27 hours (as apposed to 48 hours in women 
[111, 112]), the mean residence time (average duration of persistence in the body) to be 34 hours 
(as apposed to 59 hour in women [111]), and the volume of distribution to be 635 mL/kg (as 
apposed to 1870 mL/kg in women [111]). Taken together, we interpret these data to suggest that 
cattle may require a higher dose and a longer period of exposure to achieve effective 
concentrations in target tissues. This hypothesis is further supported by a study in which 
albendazole (another imidazole derivative used as an anthelminthic) significantly reduced 
follicular fluid estradiol concentrations in ewes when given orally at 11.5 mg/kg of body weight 
[156], which is a 46 times higher than the medium dose used in the present study.  
In summary, letrozole treatment in heifers was associated with elevated circulating LH 
concentrations and an extended period of dominance of the dominant follicle present at the time 
of treatment, regardless of dose. Consequently, circulating concentrations of FSH remained 
suppressed and emergence of the next wave was delayed. These results were unexpected and 
provide impetus for additional studies to elucidate the differences in pharmacokinetics of 
letrozole between the bovine and human species, and to explore the potential of aromatase 
inhibitors as a non-steroidal approach to the control of ovarian function in cattle. 
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5.1. EFFECTS OF A THREE-DAY REGIMEN OF LETROZOLE ON 
OVARIAN FUNCTION IN CATTLE 
5.1. Abstract 
A study was designed to determine the effects of stage of the follicular wave on ovarian 
response to letrozole in cattle, and whether a 3-day regimen of letrozole treatment can be used to 
electively control ovarian function. Post-pubertal beef heifers (N=45) were assigned randomly to 
four treatment groups. One group received no treatment (control) and the other groups were 
given 85 µg/kg of letrozole per day (250 µg/kg total dose) on Days 1 to 3, Days 3 to 5, or Days 5 
to 7 (Day 0=pre-treatment ovulation), corresponding to the period before, during and after 
selection of the dominant follicle, respectively. Follicular dynamics were monitored 
ultrasonographically and blood samples were collected for hormone assays. Follicle and CL 
diameter profiles, plasma concentrations of LH, FSH, estradiol, progesterone, and letrozole were 
analyzed. Regardless of the stage of the follicular wave in which treatments were initiated, 
multiple doses of letrozole lengthened the period of follicular dominance (P<0.01), delayed 
emergence of the next follicular wave (P<0.05), and resulted in a larger CL (P<0.01). The effects 
on dominant follicle and CL diameters appeared to be the result of increased plasma 
concentrations of LH in letrozole-treated animals. No differences were found in mean plasma 
progesterone concentration among groups. Inconsistent inhibition of estradiol production and 
variable effects on FSH secretion may be a result of insufficient circulating levels of letrozole 
during the treatment period. Higher doses of letrozole may be necessary to consistently affect 
circulating concentrations of estradiol and gonadotropins, and predictably affect follicular wave 
dynamics in cattle.  
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5.1. Introduction 
Estradiol and its esters, in combination with a source of progesterone, have been used 
effectively for synchronizing follicle wave emergence and ovulation in cattle [9, 21]. Estradiol 
has a negative feedback effect on the hypothalamo-pituitary axis causing suppression of FSH 
secretion during the luteal phase [13], or under the influence of exogenous progesterone [74], 
and has been reported to decrease LH pulse amplitude in sheep [12] and cattle [13]. Furthermore, 
luteal or exogenous progesterone reduces LH secretion, and estradiol in combination with 
progesterone cause regression of the extant dominant follicle. Once the suppressive effects of 
estradiol are removed through metabolism (42, 110, 120, 170 hours after treatment with 
estradiol-17β [157], estradiol benzoate [158], estradiol valerate [159] and estradiol cypionate 
[158], respectively), FSH surges resulting in the emergence of a new wave of follicular 
development, approximately 4 days after estradiol treatment (with E17-β and estradiol benzoate), 
regardless of the stage of development of the dominant follicle at the time of treatment [9, 20, 
21]. The degree of synchrony achieved with such treatments has made fixed-time artificial 
insemination feasible [22, 23] and improved the efficiency of multiple ovulation and embryo 
transfer programs [9, 24].  
Estrogens have also been used for several decades by the beef industry as growth promotants 
[26] because of the key role they play in linear growth and closure of epiphyseal plates, and fat 
deposition [25]. However, the use of natural or synthetic estrogens in food producing animals, 
whether for anabolic purposes or for controlling reproductive function, has been the subject of 
considerable controversy (reviewed in [31, 32]). In January 1989, as a result of increasing 
concern about potential toxic and carcinogenic effects of hormonal preparations used in food 
producing animals [29-31], estradiol and other steroid hormones were banned for use as a growth 
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promotant in animals designated for human consumption in all member states of the European 
Union [160]. In October 2006, the ban was extended to prohibit use of estradiol-17β and its 
esters for purposes of reproductive management [34]. In 2007, New Zealand and Australia 
banned use of estrogens in lactating dairy animals [161]. The use of estradiol and zeranol (an 
estrogen-like compound) as growth promotants is still permitted in the United States [119] and 
Canada [127], but no commercial preparations are available for the purposes of reproductive 
management. Hence, treatments for estrous synchronization must be custom-compounded and 
used by prescription only. Custom-compounding, however, has recently come under critical 
scrutiny in the USA [119]. This situation negatively impacts on the implementation of 
reproductive technologies in cattle production systems and limits reproductive efficiency and 
genetic improvement provided by the use of artificial insemination or embryo transfer programs 
[161]. In this context, the development of alternative methods for controlling ovarian function in 
cattle is needed.  
Letrozole, a non-steroidal aromatase inhibitor, inactivates the aromatase enzyme responsible 
for the synthesis of estrogens by reversibly binding to the heme group of the P450 subunit. 
Letrozole is indicated as an adjuvant or first-line treatment for hormone-dependent breast cancer 
in post-menopausal women [40, 120], and it has also been used in assisted reproduction in 
women because of its potential effect on removing the negative feedback of estradiol on FSH 
secretion [41-43]. For ovarian stimulation in women, it is commonly used at a dose of 1 to 5 mg 
per day for 5 days [42, 150], and it has been used in higher or increasing doses for ovarian 
superstimulation [46, 47].  
Contrary to the proposed hypothesis based on observations in women [41], treatment of beef 
heifers with single intravenous dose of letrozole on Day 3 post-ovulation did not induce 
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follicular atresia or hasten emergence of a new follicular wave (Chapter 4). Although circulating 
concentrations of estradiol were affected, letrozole treatment did not induce an elevation in 
circulating FSH concentrations. Rather, letrozole treatment increased mean plasma LH 
concentrations which resulted in a prolonged period of dominance of the extant dominant follicle 
and delayed emergence of the next follicular wave.  
The objective of the present study was to test the hypothesis that an extended period of 
letrozole exposure will terminate dominant follicle growth and result in the emergence of a new 
follicular wave at a predictable interval thereafter, regardless of the stage of follicular 
development at the time of treatment. We examined the effects of letrozole on ovarian and 
endocrine function in cattle after treatment for 3 consecutive days beginning before, during, and 
after manifest selection of the dominant follicle of the first follicular wave of the cycle.   
5.3. Material and Methods 
5.3.1. Cattle  
Hereford-cross beef heifers, 14 to 20 months of age and weighing between 233 and 404 kg, 
were chosen from a herd of 50 animals maintained in outdoor corrals at the University of 
Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers were fed alfalfa/grass 
hay and grain to gain approximately 1.3 kg per day and had water ad libitum during the 
experimental period from May to July. Heifers were initially examined by transrectal 
ultrasonography (7.5 MHz linear-array transducer, Aloka SSD-900; Tokyo, Japan) to confirm 
that they were postpubertal by the presence of a CL [143]. 
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5.3.2. Treatments and examinations 
Heifers in which a CL was detected during the initial examination underwent transvaginal 
ultrasound-guided follicular ablation of the two largest ovarian follicles to synchronize follicular 
wave emergence, which was expected to occur 1 to 1.5 days later [145, 162]. Four days after 
follicular ablation, heifers were given 500 µg of cloprostenol (PGF, Estrumate, Schering-Plough 
Animal Health, Pointe-Claire, QC, Canada) intramuscularly (im) to induce regression of the CL 
and to synchronize ovulation [144]. The experiment was performed in two replicates (n=20-27 
per replicate) and each heifer was used only once. In replicate 1, heifers were assigned randomly 
at the time of ovulation (Day 0) to the following groups and given a 3-day regimen of letrozole 
on Days 1 to 3 (n=5), Days 3 to 5 (n=5), Days 5 to 7 (n=5), or no treatment (control group, n=5). 
In replicate 2, heifers were similarly assigned to groups and given letrozole from Days 1 to 3, 
(n=5), Days 3 to 5 (n=4), or Days 5 to 7 (n=4), but untreated control heifers were arranged in 
three sub-groups to serve as contemporaneous controls for each letrozole-group during intensive 
blood sampling periods (i.e., control Days 1 to 3, n=4; control Days 3 to 5, n=4; and control 
Days 5 to 7, n=5). For practical purposes, the total dose of letrozole (250 µg/kg) was calculated 
on the basis of an average weight of 350 kg for all heifers and administered intravenously in 
daily divided doses over 3 days (85 µg/kg per day). For intravenous injection, letrozole was 
prepared in 95% ethanol to a final concentration of 5 mg/ml, resulting in an injection volume of 
6 mL/day.  
5.3.3. Ovarian ultrasonography 
Ultrasound examinations were recorded on a sketch sheet in which each ovary and its 
structures (CL [56] and follicles ≥ 4 mm in diameter [54]) were represented in size and relative 
location. Ovulation was defined as the disappearance of any follicle ≥8 mm between two 
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consecutive daily examinations, and was confirmed by the subsequent development of a CL 
[137]. Follicular wave emergence was defined retrospectively as the day when the dominant 
follicle was first identified at a diameter of 4 or 5 mm [48, 57]. If the dominant follicle was not 
identified until it reached 6 or 7 mm, the previous day was considered the day of follicular wave 
emergence [163]. The dominant follicle of a wave was defined as the largest antral follicle of 
that wave after deviation, and the first subordinate follicle as the second largest antral follicle 
originated from the same wave [146]. The day of onset of follicular and luteal regression was 
defined as the first day of an apparent constant decrease in follicular and luteal diameters, 
respectively [57].  
5.3.4. Computer-assisted ultrasound image analysis 
Ultrasound images from a subset of letrozole-treated (n=4-5 per group) and control (n=6) 
heifers were recorded throughout the duration of treatment for computer-assisted image analysis. 
Images were analyzed using a series of custom-developed computer algorithms optimized for 
ultrasonography (SYNERGYNE Version 2.8© Saskatoon, Saskatchewan) [164-166]. 
Echotexture was defined in terms of mean pixel value and pixel heterogeneity. Mean pixel 
values were quantified using a grey-scale ranging from 0 (black) to 255 (white). The pixel 
heterogeneity was the standard deviation of grey-scale values of all the pixels within the user-
defined region of measurement. Spot analysis of the follicular antrum and corpus luteum, and 
line analysis of the peripheral antrum, follicular wall and stroma were done as previously 
described [167]. For spot analyses, the follicular antrum and the CL wall were divided into four 
quadrants and the sampling area encompassed 75 to 80% of each quadrant. For line analyses, a 
straight line was drawn transversing the follicular wall from peripheral antrum to stroma and the 
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pixel values along that line were measured in areas located within the 10 and 2 o’clock position 
of the follicles [165].  
5.3.5. Collection of blood samples 
Blood samples were collected by jugular or coccygeal venipuncture into 10 ml heparinised, 
vacuum tubes (Vacutainer tubes; Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, 
USA). Blood samples were collected daily from pre-treatment ovulation to post-treatment 
ovulation. In replicate 1, additional samples were collected from letrozole-treated heifers every 
12 hours from the beginning of treatment to first wave emergence. In replicate 2, heifers were 
sampled at 15 minute intervals for the first 8 hours after the second dose of letrozole (i.e., second 
day of treatment) using an indwelling jugular catheter, as described previously [63]. Blood 
samples were centrifuged at 1500 x g for 20 minutes, and plasma was separated and stored in 
plastic tubes at -20°C. 
5.3.6. Hormone assays 
Plasma LH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay (NIDDK-bLH4) [12, 147]. The minimum and maximum values along the 
standard curve were 0.06 and 8 ng/mL, respectively. The intra- and inter-assay coefficients of 
variation were 7.9% and 2.5%, respectively, for low reference samples (mean, 0.85 ng/mL) and 
8.6% and 9.5%, respectively, for high reference samples (mean, 2.5 ng/mL).  
Plasma FSH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay using NIDDK-anti-oFSH-1 primary antibody and expressed as USDA bovine 
FSH-Il units [12, 147]. The minimum and maximum values along the standard curve were 0.12 
and 16 ng/mL, respectively. The intra- and inter-assay coefficients of variation were 11.1% and 
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11.2%, respectively, for low reference samples (mean, 1.9 ng/mL) and 5.2% and 4.1%, 
respectively, for high reference samples (mean 4.0 ng/mL). 
Plasma estradiol concentrations were determined in duplicate by enzyme-linked 
immunosorbent assay (Cayman Chemical Company, Ann Arbor, MI, USA). In this competitive 
ELISA, plasma steroid competes with acetylcholinesterase labelled steroid for the binding site on 
the polyclonal rabbit anti-steroid antibody. The antiserum to estradiol was reported to cross-react 
with estradiol-3-glucoronide (14%), estrone (12%), and estriol (0.3%). For all other steroids 
cross-reactivities were reported as <0.1%. The minimum and maximum values along the 
standard curve were 6.6 and 4000 pg/well, respectively. The intra- and inter-assay coefficients of 
variation for reference sample (100 pg/ml) assayed in duplicate were 11.7% and 12.7%, 
respectively. A concentration procedure using diethyl ether extraction was performed prior to the 
assay in all samples to increase estrogen concentration to measurable levels [148]. A 
3
H-labeled 
steroid was added to each plasma sample before extraction as an internal recovery standard. 
After the extraction procedure, a fraction of the final extract was quantified in a liquid 
scintillation counter to test for recoveries [149]. To confirm the effectiveness of the ELISA in 
quantifying estradiol concentrations in plasma, a random sub-set of plasma samples (n=25) was 
also analyzed by high performance liquid chromatography mass spectrometry (HPLC/MS) and 
results were compared to those obtained by ELISA (Appendices 3 and 4). 
Plasma progesterone concentrations were determined in duplicate using a commercial solid-
phase kit (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA, USA). The range 
of the standard curve was 0.1 to 40.0 ng/mL. The intra- and inter-assay coefficients of variation 
for samples assayed in duplicates were 10.1% and 15%, respectively, for low reference samples 
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(mean, 1.8 ng/mL) and 5.5% and 7.7%, respectively, for high reference samples (mean, 17.5 
ng/mL).  
5.3.7. Plasma letrozole concentration 
Plasma concentrations of letrozole were determined from samples collected every 12 hours 
from pre-treatment to one day after cessation of treatment using high performance liquid 
chromatography tandem mass spectrometry (LC/MS/MS) as described in Chapter 4, Section 
4.3.6.  
5.3.8. Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series hormone data, 
plasma letrozole concentration, follicular and luteal diameter profiles, were analysed by repeated 
measures, using the PROC MIXED procedure. The same test was used to compare pixel values 
and pixel heterogeneity for the dominant follicles and CL using mean values of two pre-
treatment images taken 24 hours and immediately before treatment and mean values of two post-
treatment images taken 24 and 48 hours after the end of treatment. The main effects were 
treatment, time, and their interactions. Initial inspection of LH data revealed an apparent 
difference between morning and afternoon values, so LH data were examined by analysis of 
variance for repeated measures to determine the main effects of treatment (During and After), 
stage of follicular development (Days 1 to 3, Days 3 to 5, and Days 5 to 7), time of the day (AM 
vs PM), and day of treatment (1
st
, 2
nd
, and 3
rd
 dose). Single point measurements (interwave and 
interovulatory intervals, interval from ovulation to onset of CL regression, mean and basal LH 
concentrations, LH pulse amplitude and frequency, and pharmacokinetic parameters for 
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letrozole) were analysed by analysis of variance. If no differences were detected among 
letrozole-treated groups, data were combined and re-analysed as a single letrozole treatment 
group for comparison with non-treated controls. If significant main effects or interactions (P ≤ 
0.05) were detected, Tukey’s post-hoc test was used for multiple comparisons.  
Due to individual variability in circulating hormone concentrations among heifers, and 
because our objective was to determine the effect of treatment within individuals, data on LH 
and FSH concentrations were transformed to a percentage of the mean concentration of the two 
first data points collected (Days 0 and 1) for each individual heifer before analysis of variance 
for repeated measures. For the same reasons, estradiol concentrations were transformed to a 
percentage of the mean concentration of two pre-treatment data points (i.e. for each individual 
heifer) before statistical analysis.  
For analysis of LH pulsatility from raw LH data, a pulse was defined as the presence of two 
consecutive samples (taken at 15 minute intervals) which were greater than the mean of the two 
previous samples (basal value) and one or both exceeding the mean basal value by more than 
twice the coefficient of variation of the assay [168]. The basal concentration of LH for individual 
heifers was defined as the mean of all the concentrations excluding those that were included in 
the definition of a pulse. Pulse amplitude was determined by the difference between LH pulse 
height (the highest concentration of LH within a pulse) and the basal concentration [169]. All 
values are expressed as mean ± SEM.  
Animal procedures were performed in accordance with the Canadian Council on Animal 
Care and were approved by University of Saskatchewan Protocol Review Committee. 
 
57 
 
5.4. Results 
5.4.1. Circulating concentrations of letrozole  
Plasma letrozole concentrations in all three treatment groups were elevated by 12 hours after 
initiation of treatment and reached peak levels by 60 hours, followed by a decline to 
approximately half peak values by 108 hours (time effect, P<0.001; Fig. 5.1). Heifers treated 
from Days 1 to 3 had higher circulating letrozole concentrations than those treated from Days 3 
to 5, while those treated from Days 5 to 7 were intermediate (overall means, 68.6±4.79, 
43.9±4.75 and 55.6±4.75 ng/ml, respectively, P<0.01; Fig. 5.1). 
 
Figure 5.1. Plasma letrozole concentration (mean±SEM) in heifers treated with letrozole (85 
µg/kg/day) from Days 1 to 3, Days 3 to 5 or Days 5 to 7 (Day 0 = ovulation). 
abc 
Overall means for treatment groups with no common superscript were different (P<0.05). 
 
5.4.2. Ovarian follicles and estradiol 
The diameter profile of the extant dominant follicle (i.e., the dominant follicle present at the 
time of treatment) was similar among letrozole treatment groups (Appendix 2); hence, data were 
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combined for comparison with controls. The dominant follicle grew to a greater diameter in 
letrozole-treated heifers than in controls (P<0.01; Fig. 5.2). The inter-wave interval was longer in 
letrozole-treated heifers than in controls (P<0.05; Table 5.1). However, the inter-ovulatory 
interval did not differ between groups.  
 
 
Figure 5.2. Diameter profile (mean±SEM) of the dominant follicle in heifers treated with 
letrozole on Days 1 to 3, 3 to 5 or 5 to 7 (Day 0 = ovulation; treatment groups combined, n=28) 
compared to untreated controls (n=17).  
Table 5.1. Effects (mean±SEM) of a 3-day regimen of letrozole given at three different stages of 
the follicular wave in heifers on the intervals to new wave emergence and ovulation.  
 Letrozole treatment Control  
 (n=17)  
 
Days 1 to 3  
(n=10)  
Days 3 to 5  
(n=9)  
Days 5 to 7  
(n=9)  
Inter-wave interval (days)  8.9±0.35
a
 10.0±0.37
ab
 10.7±0.37
b
 7.6±0.27
c
 
Inter-ovulatory interval 
(days) 
20.9±0.46
a 
 20.1±0.49
a
 21.2±0.49
a
 20.5±0.35
a
 
Dominant follicle diameter 
at treatment (mm)* 
6.8±0.36
a
 10.1±0.45
bc
 12.1±0.43
d
 
6.5±0.27 (Day 1)
a 
9.4±0.32 (Day 3)
b
 
11.2±0.30 (Day 5)
cd
 
abcd 
Within rows, values with no common superscript are different (P<0.05).  
* Compared to respective controls at the same stage of follicular development. 
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The diameter profile of the largest subordinate follicle in heifers treated with letrozole from 
Days 1 to 3 was larger than that of control heifers (P<0.05; Fig. 5.3). The diameter profiles of the 
largest subordinate follicle in heifers treated with letrozole from Days 3 to 5 were intermediate 
and did not differ from either of the other two groups. 
 
Figure 5.3. Diameter profile (mean±SEM) of the largest subordinate follicle in heifers treated 
with letrozole on Days 1 to 3 (n=10), or Days 3 to 5 (n=9), compared to untreated controls 
(n=17). Heifers treated with letrozole from Days 5 to 7 were not included in the analysis since 
the largest subordinate follicle was no longer detectable at initiation of treatment on Day 5. 
abc
 Overall means for treatment groups with no common superscript were different (P<0.05). 
 
Plasma estradiol concentrations for each treatment group were compared independently with 
the respective control subgroup for each treatment period (data from replicate 2; Fig. 5.4). 
Estradiol concentrations were not different between letrozole-treated and control heifers, 
regardless of the stage of follicular development at the time of treatment (Fig. 5.4).  
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Figure 5.4. Plasma estradiol concentrations, expressed as a percent of the mean of two pre-
treatment samples (i.e. taken 24 hours before and immediately before treatment; mean±SEM); in 
heifers following daily treatment with letrozole from Days 1 to 3 (a), Days 3 to 5 (b) and Days 5 
to 7 (c) of the first follicular wave (n=4-5 per group; Day 0 = ovulation). 
5.4.3. Corpus luteum and plasma progesterone 
No differences in CL diameter were detected among letrozole-treated groups; hence, data for 
the three treatment groups were combined for comparison with untreated controls. The day-to-
day CL diameter profile of heifers treated with letrozole was larger than that of controls 
(P<0.004; Fig. 5.5). Plasma progesterone concentrations did not differ among treatment groups, 
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and data were combined for comparison with controls (Fig. 5.5). Though numerically higher 
throughout the sampling period in the letrozole-treated group than in the control group, 
differences in plasma progesterone concentrations were not significant (Fig. 5.5).  
 
Figure 5.5. Diameter profile of the corpus luteum and plasma progesterone concentration (mean 
±SEM) in heifers treated with letrozole (85 µg/kg/day for 3 days; data from treatment periods of 
Days 1 to 3, 3 to 5, and 5 to 7 combined; n=18), compared to untreated controls (n=17).  
 
5.4.4. Computer-assisted ultrasound image analysis 
Spot analysis of the CL: Mean pixel values and pixel heterogeneity of images of the CL 
were not affected by letrozole treatment compared to controls. No significant changes in mean 
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pixel values or in heterogeneity were detected between pre- and post-treatment periods 
(Appendix 5). 
Spot analysis of the dominant follicle antrum: Although post-treatment values were 
consistently lower than pre-treatment values in all groups, mean pixel values and heterogeneity 
were not affected significantly by treatment during any of the three periods of the first follicular 
wave, nor was there a significant interaction of treatment and time (Appendix 5).  
Line analysis of the dominant follicle wall: Mean pixel values recorded in heifers treated 
with letrozole from Days 1 to 3 after ovulation increased (treatment by time interaction P<0.06) 
between pre- and post-treatment evaluation while it remained unchanged in control heifers. 
However, significantly lower pre-treatment samples were observed in the letrozole-treated group 
and that might account for the difference observed between controls and heifers treated from 
Days 1 to 3. There was no effect of letrozole on pre- and post-treatment mean pixel values or 
heterogeneity along the follicular wall in heifers treated on Days 3 and 5, and Days 5 and 7, 
compared to controls (Appendix 5).  
5.4.5. Gonadotropins 
No differences were detected in plasma FSH levels between letrozole-treated heifers 
compared with their respective controls (Fig. 5.6).  
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Figure 5.6. Plasma FSH concentration, expressed as a percent of the mean of Days 0 and 1 
(mean±SEM), in heifers treated with letrozole on Days 1 to 3 (n=10), Days 3 to 5 (n=9), or Days 
5 to 7 (n=9; Day 0 = ovulation), compared to untreated controls (n=17).  
No differences in plasma LH concentrations were detected among groups using daily 
samples (P = 0.78). To examine the effects on LH more critically, additional 12-hour samples 
(i.e., PM samples), originally taken in letrozole-treated heifers for measurement of letrozole, 
were also analyzed. Since PM samples were not obtained from control animals, the control group 
was not included in the analysis. Plasma LH concentrations were analyzed to determine the 
effect of time of sampling (AM vs PM), day (1
st
, 2
nd
, and 3
rd
), period (3 days of treatment vs 3 
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days after treatment), and the follicular stage when treatment was initiated (Days 1 to 3, Days 3 
to 5, or Days 5 to 7). The overall model revealed no significant effect or interaction involving 
follicular stage; hence, the effect of follicular stage was removed from the model before further 
analysis (Fig. 5.7). Interactions between day (1
st
, 2
nd
, 3
rd
) and time (AM vs PM), and between 
treatment period (during vs after treatment) and time (AM vs PM) were significant. All PM 
samples collected during treatment were significantly higher (188.5±28.50%) than AM samples 
collected during treatment (93.6±14.85%) and AM and PM samples collected after cessation of 
treatment (79.3±14.64 and 78.9±27.91%, respectively; Fig. 5.8).  
 
Figure 5.7. Comparison of plasma LH concentrations in heifers for a 60-hour period from the 
start of treatment and from the end of treatment with letrozole. Values (mean±SEM) are 
expressed as a percent of the mean of Days 0 and 1 in heifers treated with letrozole in the 
morning (AM) on Days 1 to 3 (n=10), Days 3 to 5 (n=9), or Days 5 to 7 (n=9; Day 0 = 
ovulation). Data obtained during the 3 days of letrozole treatment and the 3 days after treatment 
were analyzed for effects of Treatment (during vs after), Time of data collection (AM vs PM), 
Day (1
st
, 2
nd
, and 3
rd
), and their interactions.  
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Figure 5.8. Effect of letrozole on plasma LH concentrations (expressed as a percent of the mean 
of Days 0 and 1 post-ovulation; mean±SEM) in heifers treated in the morning for 3 consecutive 
days (letrozole-groups combined n=28) during the 3 days of treatment and after the 3 days 
following treatment.  
Plasma LH values determined in samples taken at 15 minute intervals for 8 hours after the 
second dose of letrozole were compared to their respective controls to determine the effect of 
treatment on mean and basal concentrations, pulse amplitude, and pulse frequency for each 
treatment interval (Table 5.2). No differences between letrozole vs controls groups were found 
for any of the parameters analyzed in any of the treatment periods.  
Table 5.2. Effect of 3-day letrozole treatment at three different stages of the follicular wave on 
LH secretory activity compared to corresponding controls as measured in 15 min samples 
collected over 8 hours.  
Treatment 
period 
Group 
Mean LH 
(ng/mL) 
Basal LH 
(ng/mL)  
LH pulse 
amplitude 
(ng/mL) 
LH pulse 
frequency 
(pulses/h) 
Days 1-3 
control 0.58 ± 0.12
 
0.41 ± 0.09 0.65 ± 0.20 0.92 ± 0.04 
treated 0.52 ± 0.15 0.38 ± 0.11 0.46 ± 0.15 0.95 ± 0.08 
Days 3-5 
control 0.15 ± 0.03 0.1 ± 0.03 0.21 ± 0.04 0.66 ± 0.08 
treated 0.15 ± 0.5 0.08 ± 0.03 0.40 ± 0.18 0.53 ± 0.03 
Days 5-7 
control 0.15 ± 0.06 0.09 ± 0.03 0.45 ± 0.11 0.41 ± 0.06 
treated 0.21 ± 0.04 0.13 ± 0.02 0.88  0.37 0.41 ± 0.08 
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5.5. Discussion 
In the present study, a 3-day letrozole treatment of post-pubertal beef heifers at different 
stages of development of the dominant follicle of the first follicular wave did not consistently 
decrease circulating estradiol concentrations, nor did it induce a surge in FSH, or hasten 
emergence of a new follicular wave as was hypothesized. On the contrary, letrozole treatment 
caused the extant dominant follicle to grow larger and prolonged its period of dominance, 
extending the interval to emergence of the next follicular wave. In women, treatment with 
letrozole from Days 3 to 7 after the beginning of menses has been reported to cause emergence 
of a new wave of follicular development shortly after the initiation of treatment [42]. The 
mechanism responsible for this effect was hypothesized to involve removal of the negative 
feedback effect of estradiol on pituitary FSH secretion resulting in an endogenous surge in 
plasma FSH which recruits a new cohort of growing follicles [41-43]. The reason(s) for these 
differences between species are not immediately clear. 
The dominant follicle diameter profiles reported herein document that 85 µg/kg/day of 
letrozole given intravenously in a 3-day regimen (250µg/kg total) did not terminate dominant 
follicle growth, regardless of whether treatment was initiated before, during or after selection of 
the dominant follicle. Continued growth of the dominant follicle, as well as the CL, was 
attributed to increased circulating concentrations of LH in letrozole-treated heifers [170]. Results 
from computerized image analysis supported the notion that dominant follicle viability was not 
modified by letrozole treatment during any of the treatment stages assessed in the present study.  
Another unexpected finding was the continued growth of the largest subordinate follicle in 
heifers treated with letrozole from Days 1 to 3 after ovulation; it grew larger and for longer 
67 
 
period of time compared to controls. Although this observation resembled an FSH-dependent 
superstimulatory effect [57, 78], it was not associated with an increase in circulating 
concentrations of FSH. Perhaps elevated LH was responsible for continued growth of 
subordinate follicles during treatment on Days 1 to 3. Growing follicles within a follicular wave 
are FSH-dependent to approximately 3 days after wave emergence when LH receptors begin to 
express, leading to a shift in gonadotrophin responsiveness [48, 49, 57, 61, 139]. As this shift to 
LH responsiveness is not an all-or-nothing phenomenon, as subordinate follicles are capable of 
assuming dominance [171], it is plausible that growing subordinate follicles become responsive 
to LH before selection is complete (e.g., Day 2 of the follicular wave) and that elevated LH 
concentrations induced by letrozole treatment were stimulatory to the growth of the largest 
subordinate follicle [172].  
A treatment-induced-cycle-like pattern of LH secretion was observed in the three letrozole-
treated groups; an elevation of LH concentrations occurred by 12 hours after treatment followed 
by a decline to baseline within 24 hours. Although the understanding of ultradian or circadian 
variations on LH secretion in cattle and other mammals is contradictory [166, 173, 174]; the fact 
that evening increases in circulating LH concentrations were present only during letrozole 
treatment tends to rule out a diurnal-nocturnal variation as a cause for such increases.  
The effect of letrozole treatment on mean plasma estradiol concentrations was inconsistent 
among the three treatment periods assessed in this experiment. Although not significant, it 
appeared that heifers receiving letrozole from Days 5 to 7 after ovulation had higher plasma 
estradiol concentrations compared to controls. This third treatment period encompassed the 
early/late static phase of the dominant follicle, a time when estrogen synthesis might be expected 
to start declining. However, after treatment with letrozole from Days 5 to 7 post-ovulation, the 
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dominant follicle remained viable and produced estradiol for a longer period of time; thus, wave 
emergence did not occurred, on average, until Day 10.7 post-ovulation (vs Day 7 in control 
heifers). 
Unexpectedly, letrozole concentrations were lower in heifers treated from Days 3 to 5 than 
those treated from Days 1 to 3, although this observation may be due to differences in real body 
weight among heifers within each treatment group. The mean circulating concentrations of 
letrozole 96 hours after 250 µg/kg given in a 3-day regimen or as a single dose were similar 
(51.6±4.33 ng/mL vs 43.7±8.79 ng/mL, respectively). However, during the first 96 hours after 
initiation of treatment, the mean circulating levels of letrozole in the 3-day protocol were lower 
compared to those of heifers given the same dose in a single application (60.8±3.36 vs 
112±16.26 ng/ml). It could be speculated that the single injection of letrozole at a dose of 250 
µg/kg was marginal in suppressing estradiol production, while splitting this dose into three daily 
injections resulted in sub-thresh-hold doses that failed to inhibit estradiol production in this 
study.  
In summary, 250 µg/kg of letrozole, given in a 3-day regimen, elevated LH secretion 
resulting in larger dominant follicle and CL profiles and prolonged interwave intervals, 
regardless the stage of follicular development during which treatment was applied. Follicle 
stimulating hormone levels in plasma were not affected by letrozole administration during any of 
the treatment periods. We speculate that the inconsistent and minimal inhibition of estradiol 
production accounts for the lack of effect on FSH secretion. Based on the circulating 
concentrations of letrozole achieved in this study, it could be concluded that a total dose of 250 
µg/kg of letrozole divided into three doses of 85µg/kg is insufficient to consistently inhibit 
aromatase activity and estradiol secretion. Thus, the results continue to support the notion that 
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higher levels of letrozole may be needed to achieve a consistent and durable inhibition of 
estradiol production necessary to predictably affect gonadotropin secretion and follicular 
dynamics in cattle. 
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6. GENERAL DISCUSSION 
Letrozole is a non-steroidal aromatase inhibitor that has been used for treatment of hormone-
dependent breast cancer in women [120]. When administered to premenopausal women, 
letrozole has been reported to have a stimulatory effect on ovarian function, and has been used 
for the purpose of follicular stimulation and induction of ovulation [41] and ovarian 
superstimulation [46, 47]. We hypothesized that letrozole could be used to manipulate and 
synchronize ovarian follicular wave dynamics in cattle. 
Two experiments were conducted to determine the effects of letrozole treatment on 
endocrine function and follicular dynamics in cattle. We examined: 1) the effects of three doses 
of letrozole administered as a single intravenous injection on follicular dynamics, gonadotropin 
release and estradiol production (Chapter 4); and, 2) the effect of a 3-day regimen of letrozole on 
follicular and luteal dynamics, gonadotropin release, and estradiol and progesterone production 
when given before, during or after dominant follicular selection (Chapter 5).  
The objective of this section is to summarize and integrate the results obtained from the 
experiments presented in Chapters 4 and 5 of this thesis to current information available in the 
literature. Although most of the studies in which letrozole has been used as a fertility therapy 
have been conducted in women, the validated bovine model allows for the comparison of results 
reported in this thesis with those reported in humans [136, 140]. However, the limitations of 
these comparisons will be acknowledged when pertinent. 
In women, it has been proposed that letrozole treatment interrupts dominant follicle 
maturation and by eliminating the negative feedback effects of estradiol on the pituitary gland, 
induces a surge in circulating FSH concentrations resulting in the emergence of a wave of 
follicular growth [41-43, 150]. However, there does not appear to be any scientific reports where 
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such effects on follicular dynamics in women were critically determined. The studies included in 
this thesis failed to show that a single treatment of letrozole on Day 3 post-wave emergence 
(Chapter 4), or a 3-day-regimen of letrozole given before, during or after dominant follicle 
selection (Chapter 5) would induce the regression of the dominant follicle and the emergence of 
a new follicular wave. Conversely, letrozole treatments in both studies effectively lengthened the 
period of dominance of the extant dominant follicle and resulted in a prolonged interval to 
emergence of the next follicular wave. Further, the mean diameters achieved by the extant 
dominant follicle and CL were significantly larger in letrozole-treated heifers.  
Contrary to our hypothesis, none of the letrozole-treated groups examined in Chapters 4 and 
5 had significantly increased circulating concentrations of FSH compared to controls. This 
observation explained the failure to induce a wave of follicular development after letrozole 
treatment. Studies conducted in rats [151] and bonnet monkeys [175] provided evidences to 
support the notion that letrozole treatment would increase FSH levels. Despite clinical 
impressions to the contrary, no such results have been documented in women. Cortinez et al. [45] 
found no effect of a 5-day letrozole treatment protocol from Days 3 to 7 after onset of menses on 
FSH levels compared to control cycles, and Fisher et al. [131] found no effect of a 5-day regimen 
of letrozole from Days 5 to 9 after onset of menses. Our observations suggest that letrozole 
treatment does not have an effect on pituitary FSH secretion in cattle at the doses evaluated in 
the two trials included in this thesis. The immediate reasons for the unchanged FSH levels are 
not remain poorly elucidated. Although estradiol production may have been at least marginally 
affected by letrozole treatment given once (Chapter 4) or in a 3-day regimen (Chapter 5), follicle 
growth continued. In addition, rather that regressing, the dominant follicle had an extended life-
span. Thus, the suppressive effect of inhibin and other follicular products that would be produced 
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by the persistent follicle may account for the unchanged FSH levels reported herein [115, 155, 
168, 176-178]. 
It must be accepted that the lack of a marked suppressive effect of letrozole on estrogen 
concentrations in cattle in the studies reported in this thesis may have been due to an inadequate 
dosage. To our knowledge, there are no published data comparing different doses or regimens of 
letrozole treatment for ovarian stimulation in cattle. The medium dose (250 µg/kg) of letrozole 
used in Chapter 4 was determined by calculations based on a study conducted in women in 
which a single dose of 20 mg of letrozole seemed to be comparable to a 5-day regimen of 
letrozole for ovarian stimulation [130]. We calculated that the amount of letrozole administered 
to a woman weighting, on average, 75 kg was about 250 µg/kg; we determined the high and low 
doses as twice and a half of the medium dose, respectively, using this study as reference. We 
speculated that 250 µg/kg of letrozole divided in a 3-day regimen (Chapter 5) should be able to 
induce the hypothesized changes on ovarian function. In Chapter 4, mean plasma estradiol 
concentrations in letrozole-treated heifers tended to be higher than in controls for the first 4 days 
after treatment, although plasma estradiol concentrations decreased by nearly 50% by 24 hours 
after a single treatment with letrozole. This result was attributed to a significant and sharp 
elevation in circulating estradiol concentrations 12 hours after letrozole administration. The 
increase in estradiol synthesis may have been caused by increased LH secretion induced by the 
initial decrease in estradiol concentrations following letrozole treatment. The rebound in 
estradiol production may also have been triggered by substrate accumulation (androgens) after 
letrozole-induced aromatase inhibition.  
The inconsistent effect of letrozole treatment on estradiol production may have been 
responsible for the unchanged FSH concentrations observed in both trials. Additionally, 
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treatment with letrozole during Days 1 to 3 after ovulation (Chapter 5) resulted in the 
synchronous development of two follicles (dominant follicle plus largest subordinate) for the 
duration of treatment, both of which may have been actively secreting estrogens. Thus, the 
amount of estradiol secreted “per follicle” in this treatment group may have been reduced by 
letrozole administration, however the total amount measured in plasma did not differ due to the 
additive effect of both follicles.  
Letrozole treatment reduced estrogen levels by 90% at 24 hours and levels remained low for 
at least 168 hours post-treatment when given to boars at a dose of 0.1 mg/kg body weight [152]. 
Rats treated with 0.5 to 5 mg/kg/day of letrozole had an 80% reduction in ovarian tissue estradiol 
levels compared to untreated controls [151]. In humans, estrogen suppression was 97 to 99% in 
post-menopausal women [114, 120], and 30% and 90%, respectively, with the lowest (0.02 mg) 
and the highest (30 mg) dose of letrozole tested in healthy male volunteers [109]. It is important 
to highlight, however, that levels of inhibition of about 50% were reported in premenopausal 
bonnet monkeys treated with 3.5 mg of letrozole over 7 days (from Days 7 to 14 of the menstrual 
cycle) [175] and in premenopausal women treated with 5 mg/day of letrozole from Days 3 to 7 of 
the menstrual cycle [45]. Collectively, it appears that estradiol inhibition by letrozole treatment is 
more profound in males (boars and men) and in post-menopausal women than in premenopausal 
women and non-human primates. It is recognized that differences in doses and regimens of 
administration of letrozole, as well as methods used for determination of estradiol levels in 
plasma, serum or ovarian tissue must be taken into consideration in the interpretation of these 
results. It is also recognized that the inherently low estradiol concentration in non-pregnant cattle 
and the sensitivity of the estradiol assay used in these experiments may have made it difficult to 
demonstrate an effect of letrozole treatment in the experiments reported herein. However, these 
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results also lead one to the conclusion that higher levels of letrozole are needed to effectively 
suppress estradiol production in cattle, especially with the greater amount of estradiol produced 
by the ovaries of cyclic cattle.  
The continued growth of the dominant follicle (Chapter 4 and 5) and enhanced development 
of the CL (Chapter 5) following letrozole treatment were probably the result of the higher plasma 
LH concentrations observed in letrozole-treated animals [15, 18]. It has been shown that 
increased LH pulse frequency can maintain and extend follicular dominance, delaying the 
emergence of a new wave of follicular development. The results of several studies have led to 
the conclusion that LH levels are suppressed by luteal concentrations of progesterone [15, 18] in 
conjunction with the feedback effect of estradiol on gonadotrophin secretion during progesterone 
influence [13]. Hence, if letrozole treatment did reduce estradiol production in the present 
studies, the pituitary secretion of LH may have been released from the negative feedback effect 
of estradiol and been responsible for the increased plasma LH concentrations we observed. Our 
results are in agreement with the study by Cortinez et al. in which a larger follicular size in 
letrozole-treated women was also attributed to the higher levels of LH found in circulation [45]. 
Similar effects of prolonged dominance have been observed in postpartum beef cows following 
exogenous pulsatile administration of LH [179]. An interesting observation was that despite 
prolonged dominance in letrozole-treated animals, there was no difference in the interovulatory 
interval between letrozole-treated and control heifers during the 3-day treatment regimen 
(Chapter 5). We therefore speculate that the increased LH concentrations following letrozole 
treatment occurred too early in the luteal phase (last letrozole treatment was given on Day 7 post-
ovulation) to affect the life-span of the CL. Letrozole treatment later in the luteal phase may very 
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well delay luteolysis by maintaining higher circulating levels of LH, thereby lengthening the 
interovulatory interval.  
The elevated levels of LH reported in letrozole-treated animals may also have also been 
responsible for the sustained growth of the second largest follicle in heifers treated with letrozole 
from Days 1 to 3 post-ovulation (Chapter 5). Although this observation resembled an FSH-
dependent superstimulatory effect [57, 78], it was not associated with an increase in circulating 
concentrations of FSH. Growing follicles are FSH-dependent until approximately 3 days after 
wave emergence when LH receptors begin to express [48, 49, 57, 61, 139]. As the shift to LH 
responsiveness is not an all-or-none phenomenon (subordinate follicles are capable of assuming 
dominance [171]), it is plausible that growing subordinate follicles become responsive to LH 
before selection is complete (e.g., Day 2 of the follicular wave). Therefore, elevated LH 
concentrations resulting from letrozole treatment may have been stimulatory to the growth of the 
largest subordinate follicle [172]. This same mechanism may be responsible for the growth of 
more than one dominant follicle observed in women undergoing letrozole ovarian 
superstimulation [45-47]. The same results (more than one pre-ovulatory sized follicle) 
potentially could be achieved in cattle by extending the period of letrozole treatment. However, it 
is unclear whether the stimulatory effects of LH on follicular maturation involve increased 
estradiol production or if LH is able to directly stimulate mitosis and differentiation of granulosa 
and thecal cells without steroid hormones as mediators.  
The pharmacokinetic study of plasma from heifers treated intravenously with a single dose 
of 125, 250 or 500 µg/kg of letrozole resulted in circulating concentrations of letrozole that 
differed from that reported in humans. Letrozole seemed to have a shorter half-life in heifers than 
in humans (on average, 27 vs 48 hours) and the mean residence time (MRT) value (representing 
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the average duration of persistence of the drug in the body) was almost half that reported in 
humans (33.7 hours in heifers vs 58.7 hours in women [111]). The volume of distribution 
observed in the heifers (635 mL/kg) was also lower than that reported in women (1870 mL/kg) 
[111]. Collectively, these data may be interpreted to mean that letrozole appears to be more 
rapidly cleared from circulation in cattle than in humans. Thus, higher or more frequent doses of 
letrozole may be needed to achieve effective circulating levels in cattle as compared to women. 
The method for measurement of letrozole in plasma in these studies was not completely 
validated; therefore, the pharmacokinetic parameters must be interpreted with caution. Further 
pharmacologic determinations need to be performed to confirm these findings.   
Determining the minimal effective dose of letrozole that results in consistent inhibition of 
estradiol production in cattle is essential to explore the endocrine and paracrine mechanisms 
affected by estrogen deprivation. The hypothesis proposed to explain the effects of letrozole 
treatment on FSH secretion and ovarian function in humans was not supported, but quite 
unexpectedly, an effect on LH secretion was observed. Ovarian function was affected by 
letrozole treatment and it is now important to investigate the various endocrine inter-relationship 
that are involved and how this unexpected finding might be used for the expressed purpose of 
controlling ovarian function. Aromatase inhibitors represent a potentially safe, steroid-free 
method to control ovarian function in cattle. The observed effects should be confirmed and 
pursued, and the putative mechanisms of action of letrozole on follicular dynamics in women 
may need to be reconsidered. 
We propose a new mechanism of action of the aromatase inhibitor letrozole on ovarian 
stimulation in cattle in which estradiol inhibition affects LH secretion without altering FSH 
release. The increased LH concentrations resulting from letrozole treatment caused continued 
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growth of the extant dominant follicle, which could result in improved ovulatory response after 
hCG or GnRH treatment. Furthermore, increased LH levels apparently stimulated the 
development of subordinate follicles to a state of maturation in which they may have gained 
responsiveness to an LH pre-ovulatory surge, potentially leading to multiple ovulations.  
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7. GENERAL CONCLUSIONS 
The results of the experiments included in this thesis and the related literature have led to the 
conclusion that the general hypothesis that letrozole treatment would terminate growth of 
dominant follicle by suppressing estradiol production, followed by a surge in FSH secretion and 
the emergence of a new wave of follicular development was not supported. However, results are 
supportive of an alternative hypothesis relating to the control of ovarian function through 
increased LH secretion following letrozole treatment. 
The specific conclusions of this thesis are: 
1) Chapter 4: Effects of letrozole on ovarian function in cattle 
a. Letrozole given once intravenously at a dose of 125, 250 or 500 µg/kg on Day 4 
post-follicular ablation in postpubertal beef heifers is not able to significantly 
reduce plasma estradiol concentrations. 
b. Letrozole given once intravenously at a dose of 125, 250 or 500 µg/kg on Day 4 
post-follicular ablation in postpubertal beef heifers is not able to significantly 
reduce dominant follicle growth. 
c. Letrozole given once intravenously at a dose of 125, 250 or 500 µg/kg on Day 4 
post-follicular ablation in postpubertal beef heifers does not induce a surge on 
FSH secretion, but significantly increases circulating LH levels. 
d. Higher circulating levels of LH observed following the intravenous administration 
of letrozole at a dose of 125, 250 or 500 µg/kg in heifers on Day 4 post-follicular 
ablation can stimulate continued growth of the extant dominant follicle and 
prolong the interwave interval. 
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e. Based on the apparent 20 hours shorter half-life of letrozole in the circulation of 
heifers compared to humans, a more prolonged treatment (i.e., multiple doses) 
may be necessary to effectively suppress estradiol production in cattle. 
2) Chapter 5: Effect of a 3-day regimen of letrozole on ovarian function in cattle 
a. A dose of 250 µg/kg of letrozole given in a 3-day regimen (85 µg/kg/day) to 
postpubertal beef heifers does not significantly reduce estrogen production. 
b. Letrozole given in a 3-day regimen of 85 µg/kg/day to postpubertal beef heifers 
does not terminate growth of the extant dominant follicle regardless of the stage 
of follicular development at the time of initiation of treatment.  
c. Letrozole given in a 3-day regimen of 85 µg/kg/day to postpubertal beef heifers, 
regardless the stage of follicular development at the time of initiation of treatment 
does not directly affect FSH secretion, but significantly increases circulating LH 
levels. 
d. Higher circulating levels of LH observed in heifers after a 3-day regimen of 85 
µg/kg/day of letrozole result in a larger mean dominant follicle and CL diameters 
and the prolonged interwave intervals. 
e. Data suggest that it may be possible to induce ovarian superstimulation by 
continuing treatment with letrozole to maintain the growth of the dominant and 
larger subordinate follicles. 
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8. FUTURE STUDIES 
Based on observations made in this thesis, I propose that the following research questions 
need to be addressed: 
 Would a higher dose of letrozole (i.e., 1 mg/kg) be more efficacious in reducing 
circulating levels of estradiol? 
 Are the pharmacokinetic parameters of letrozole reported herein accurate? Can the 
vehicle or route of administration significantly alter those pharmacokinetic 
parameters? 
 If estradiol production is effectively inhibited, would that cause increased FSH 
secretion? 
 Which non-steroidal follicular factors, if any, are preventing the increase in FSH 
secretion before and after follicular selection?  
 Can a long-term treatment with letrozole stimulate the growth of subordinate follicles 
to ovulatory size? Can these subordinate follicles be induced to ovulate? 
 Can letrozole treatment prevent the pre-ovulatory estradiol surge? Could this be used 
in women as emergency contraception treatment? 
 Is estradiol required for the normal growth and maturation of the dominant follicle?  
 Does the inhibition of estradiol affect oocyte competence? 
 How can letrozole be used for the synchronization of ovarian function in cattle? 
 Is bovine model an effective method to study the effects of letrozole on ovarian 
function in humans? 
 Can the effects of letrozole on LH secretion be used to manipulate ovarian function in 
cattle, or humans? 
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APPENDICES  
APPENDIX 1: Diameter profile (mean ± SEM) of the dominant follicle in heifers treated with a 
high- (n = 9), medium- (n = 10) or low-dose (n = 10) of letrozole 4 days after follicular ablation 
(i.e., 2.5 days after wave emergence), compared to saline-treated controls (n = 10). 
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APPENDIX 2: Diameter profile (mean±SEM) of the dominant follicle in heifers treated with 
letrozole on Days 1 to 3 (n = 10), 3 to 5 (n = 9) or 5 to 7 (n = 9) (Day 0 = ovulation) compared to 
untreated controls (n = 17). 
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APPENDIX 3: Determination of plasma estradiol-17β concentrations by liquid 
chromatography/mass spectrometry 
Plasma concentrations of estradiol were determined using high performance liquid 
chromatography/mass spectrometry (HPLC/MS). To extract estradiol from the samples, 100 µL 
of surrogate standard (500 pg/mL d4-E2, deuterated form of estradiol-17β) were added to 1.5 mL 
of plasma followed by the addition of 3 mL of methanol. The mixture was diluted (10% v/v 
methanol) with nanopure water. A solid phase extraction of the samples was accomplish using 
Oasis® HLB cartridges (hydrophilic lipophilic balance; Waters, Milford, MA, USA). Prior to 
extraction, the cartridges were fitted onto a solid-phase extraction (SPE) vacuum manifold and 
were sequentially conditioned with 6 mL of ethyl acetate, 6 mL of acetonitrile and finally 12 mL 
of nanopure water. After conditioning, samples were loaded, and after passing trough, the 
cartridges were dried by negative pressure. The retained compounds were eluted with 12 mL of 
ethyl acetate. After dried under gentle nitrogen flow, the residues were dissolved in 4 mL of 
hexane/ethyl acetate (v/v, 9:1) and transferred to a 12 mL glass bottle. Additional 2 mL of 
nanopure water were added to the 12 mL bottle and after shaking and separation, the organic 
layer was removed by pipetting and transferred to a 4 mL glass bottle. After drying the organic 
solvents, addition of hexane/ethyl acetate (v/v, 9:1) and transfer of organic layer to the same 4 
mL bottle was repeated twice. This second tube was dried by gentle nitrogen gas flow. The dried 
extract was resolved with NaHCO3 buffer (0.1 mL) and dansyl chloride agent (1mg/mL, 0.1 mL) 
for derivatization, and it was shaken for 1 minute and heated at 60ºC for 5 minutes. After it 
cooled, 1 mL of nanopure water and 2 mL of hexane/ethyl acetate (v/v, 9:1) were added and the 
organic layer were transferred to a fresh 4 mL glass bottle. This last liquid extraction was 
repeated two more times. Finally, the extract was dried under nitrogen gas flow and the residues 
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were reconstituted in 80µL of acetonitrile plus 20 µL of nanopure water prior analysis using LC-
MS/Ms. Separation was accomplished by HPLC (Agilent 1200, Santa Clara, CA, USA) fitted 
with an analytical column (100x2.1 mm, 5.0 µm particle size; Thermo Scientific Betasil C18, 
Waltham, MA, USA) operated at 30ºC. The mobile phase consisting of acetonitrile (solvent A) 
and 0.1% formic acid in water (solvent B) was used with a gradient elution of A:B = 80:20 to 
95:5 (0-15 min) and 80:20 (15-20 min) at a flow rate of 0.25 mL/min. Mass spectra were 
collected using a tandem mass spectrometer (Applied Bioscience SCIEX 3000, Foster City, CA, 
USA) fitted with an electrospray ionization source, operated in the positive ionization mode. 
Chromatograms were recorded using multiple reaction monitoring (MRM) mode, where at least 
two transitions per-analyte were monitored. The following instrument parameters were used: 
desolvation temperature 475ºC, desolvation (curtain) gas 8.0 arbitrary units (AU), nebulizer gas 
flow 12 AU, ion spray voltage 3750 V, collision gas 12 AU, collision energy 48 AU, 
declustering potential 70 AU, and a dwell time of 200 msec. Quantification using these 
transitions was performed using Analyst 1.4.1 software provided by SCIEX (Applied Bioscience, 
Foster City, CA, USA). The minimum and maximum values along the standard curve were 40 
and 20000 pg/mL respectively. The limit of quantification used in this method was 10 pg/mL and 
the mean recovery was 70%. The LOD and LOQ in the plasma are 0.8 pg/mL and 2 pg/mL. CV 
was less than 5%. 
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APPENDIX 4: Comparison of plasma estradiol-17β concentration as determined by high 
performance liquid chromatography (HPLC/MS) and enzyme-linked immunosorbent assay 
(ELISA). 
 A sub-set of plasma samples (n=20) was analyzed by HPLC/MS to determine plasma 
estradiol-17β concentration and to be compared with the results obtained by ELISA. 
Unexpectedly, two plasma samples failed to induce a peak on the mass spectrometer and they 
could not be measured. The data obtained by HPLC/MS and ELISA, together with the 
coefficient of variation (CV) between the two methods of determination are summarized in the 
following table: 
 Plasma E-17β concentration  
Sample LC/MS Elisa CV 
A 164 160.2 1.7 
B 66.4 58.5 9.0 
C 3.0 3.4 7.9 
D 10.9 12.9 11.9 
E 330 296.6 7.5 
F 4.9 3.4 26.9 
G 4.34 6.0 22.9 
H 4.5 3.4 20.4 
I 10.2 11.4 7.7 
J 5.08 5.3 3.0 
K 6.2 5.4 9.4 
L 11.8 11.3 3.1 
M 17.3 18.3 3.6 
N 15.1 15.1 0.2 
O 8.7 7.0 15.3 
P 12.5 12.0 2.9 
Q 70.1 73.6 3.4 
R 11.9 16.9 24.2 
  Mean CV 10.1 
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APPENDIX 5: Results from computer-assisted image analysis of CL and dominant follicle 
 
 
Mean pixel values (mean±SEM) and pixel heterogeneity (mean±SEM) of the CL recorded by 
spot analysis. Pre- and post-treatment values were compared within each treatment period (Days 
1 to 3, Days 3 to 5 or Days 5 to 7) with contemporary controls. 
 
Mean pixel values (mean±SEM) and pixel heterogeneity (mean±SEM) of the follicular antrum 
recorded by spot analysis. Pre- and post-treatment values were compared within each treatment 
period (Days 1 to 3, Days 3 to 5 or Days 5 to 7) with contemporary controls. 
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Mean pixel values (mean±SEM) and pixel heterogeneity (mean±SEM) along the follicular wall 
recorded by line analysis. Pre- and post-treatment values were compared within each treatment 
period (Days 1 to 3, Days 3 to 5 or Days 5 to 7) with contemporary controls. 
 
